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Chapter - 1                                                                                                 Introduction
Oral delivery of drugs is by far the most preferred route of drug delivery due to ease
of administration, patient compliance and flexibility in formulation  [1]. Conventional
oral  dosage  forms  provide  a  specific  drug  concentration  in  systemic  circulation
without offering any control over drug delivery [2]. These systems achieve as well as
maintain  drug  concentration  within  therapeutically  effective  range  needed  for
treatment only when taken several times a day. This results in significant fluctuation
in drug levels [3].
Now-a-days most of the pharmaceutical scientists are involved in developing an ideal
drug  delivery  system  (DDS).  An  ideal  oral  drug  delivery  system  should  steadily
deliver  a  measurable  and  reproducible  amount  of  drug  to  the  target  site  over  a
prolonged period [4].
Controlled release drug delivery systems:
Controlled  release  drug  delivery  systems  (CRDDS)  provide  drug  release  at  a
predetermined,  predictable  rate  and  optimizes  the  therapeutic  effect  of  a  drug  by
controlling its release in the body with lower and less frequent dosing [2],[4].
In general controlled delivery attempts to [5]:-
a) Sustain drug action at a predetermined rate by maintaining a relatively constant
and effective drug level in the body with concomitant minimization of undesirable
side effects associated with a saw tooth kinetic pattern.
b) Localize drug action by spatial placement of controlled release system (usually
rate controlled) adjacent to or in the diseased tissue or organ.
c) Target drug action by using carriers or chemical derivatization to deliver drugs to
a particular target cell type.
In practice,  very few of the applied systems embrace all of these actions. In  most
cases the release system creates constant concentration of drug within the body over
an extended period of time. In order to maintain a constant drug level in either plasma
Department of Pharmaceutics                     J.K.K.M.M.R.F College of Pharmacy
1
Chapter - 1                                                                                                 Introduction
or target  tissue,  release rate from controlled release system should be equal to the
elimination  rate  from  plasma  or  target  tissue.  The  most  conventional  method  to
achieve  a constant  plasma level  is  the use of  intravenous  infusion.  However,  this
would be inconvenient for most therapeutic situations so that other non-invasive route
such as the oral or transdermal route is preferred.
For  conventional  drug  delivery  systems,  rate-limiting  step  in  drug  availability  is
usually absorption of drugs across a biological membrane such as the gastrointestinal
wall. However in a sustained / controlled release product one aims for release of drug
from the dosage form as the rate limiting step. Thus drug availability is controlled by
the kinetics of drug release rather than absorption [5].
Advantages of controlled release dosage forms [6]:
Some of the advantages of controlled release (CR) dosage forms (DFs) include, 
• Reduction in dosing frequency.
• Reduced fluctuation in circulating drug levels.
• Increased patient compliance.
• Avoidance of night time dosing.
• More uniform effect
• Reduction in gastrointestinal (GI) irritation.
• Reduction in other dose-related side effects.
Disadvantages of controlled release dosage forms:
Controlled release dosage forms (CR-DFs) have several potential disadvantages. They
include,
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• Cost, Unpredictable, Often poor in vitro – in vivo correlation.
• Dose dumping, reduced potential for dosage adjustment.
• Increased potential for first pass clearance leading to poor systemic availability.
• In general effective drug release period is influenced and limited by GI residence
time [6].
A major constraint in oral controlled drug delivery is that not all drug candidates are
absorbed  uniformly  throughout  the  gastrointestinal  tract  (GIT).  Some  drugs  are
absorbed only in a particular portion of GIT or are absorbed to a different extent in
various segments of the GIT. An absorption window exists because of physiological,
physicochemical  or biochemical  factors.  The pH dependent solubility and stability
level  of a drug plays  an important  role in its  absorption. Because  most drugs are
absorbed  by  passive  diffusion  of  the  unionized  form,  the  extent  of  ionization  at
various pH levels can lead to non-uniform absorption or an absorption window. The
presence of certain enzymes in a particular region of the GIT also can lead to regional
variability in absorption of drugs that are substrates of these enzymes [2].
Drugs having site-specific absorption are difficult to design as oral CRDDS, because
the  drug  released  in  the  region  preceding  and  in  close  vicinity  to  the  absorption
window is only available for absorption. After crossing the absorption window the
released  drug  goes  to  waste  with  negligible  or  no  absorption.  This  drastically
decreases the time available for drug absorption after its release and jeopardizes the
success of the delivery system [2].
The  design  of  oral  controlled  drug  delivery systems  (DDS)  is  primarily  aimed to
achieve more predictable and increased bioavailability. However these systems have
several physiological difficulties, such as inability to restrain and localize the DDS
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within desired regions of the GI tract and highly variable nature of gastric emptying
process. 
Gastric  emptying  time in  humans,  which  is  normally  2-3 hours  through the main
absorption area (stomach or upper part of intestine), can result in incomplete drug
release from DDS leading to diminished efficacy of administered dose. The intimate
contact  of the DDS with absorbing membrane has the potential  to maximize drug
absorption and may also influence rate of drug absorption. These considerations are
development of oral controlled gastro retentive dosage forms [4].
GASTRO RETENTIVE DRUG DELIVERY SYSTEMS:
Dosage form is retained in stomach are called gastro retentive drug delivery systems
(GRDDS). GRDDS is improved controlled delivery of drugs and absorption window
by continuously releasing the drug for a prolonged period of time before it reaches its
absorption site, thus ensuring its optimal bioavailability [2].
Drugs  having  narrow  absorption  window  are  mostly  associated  with  improved
absorption at  jejunum and ileum due to  enhanced  absorption properties  e.g.  large
surface area, or enhanced solubility in stomach as opposed to the more distal parts of
the GIT [8].
Figure 1: Drug absorption in the case of (a) Conventional dosage forms
(b) Gastro retentive drug delivery systems [2].
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Certain types of drugs using gastro retentive devices include [7]:-
• Drugs acting locally in stomach e.g. Antacids
• Drugs that are primarily absorbed in stomach e.g. Albuterol
• Drugs that are poorly soluble at an alkaline pH
• Drugs with a narrow window of absorption e.g. drugs that are absorbed mainly
from the proximal small intestine e.g. Riboflavin, Levodopa
• Drugs absorbed rapidly from GI tract e.g. Amoxicilin
• Drugs that degrade in colon e.g. Metoprolol.
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Longer residence time in stomach could be advantageous for local action in the upper
part of small intestine, for example treatment of peptic ulcer disease.
Advantages of Gastro retentive drug delivery systems [9]:
• Enhanced bioavailability.
• Enhanced first-pass biotransformation.
• Sustained drug delivery/reduced frequency of dosing.
• Targeted therapy for local ailments in the upper GIT.
• Reduced fluctuations of drug concentration.
• Improved selectivity in receptor activation.
• Reduced counter-activity of the body.
• Extended time over critical (effective) concentration.
• Minimized adverse activity at the colon.
• Site specific drug delivery.
Ideal drug candidates for compounding into GRDFs [8]:
a) Drugs stable in gastric milieu.
b) Drugs having narrow absorption window.
c) Drugs to be used for gastro-duodenal local therapy.
Drugs incorporated into GRDFs [8]:
The  following  are  the  list  of  drugs  that  have  been  incorporated  into  GRDFs  as
microspheres, granules, capsules, tablets or pills.
Acyclovir Alendronate Atenolol
Captopril Cinnarizine Ciprofloxacin
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Cisapride Furosemide Glipizide
Ketoprofen Levodopa Misoprostol
Nicardipine Riboflavin Tetracycline
Verapamil Diltiazem
Disadvantages of Gastro retentive drug delivery systems [9]:
• The drugs that may irritate the stomach lining.
• The drugs  are  unstable  in  its  acidic environment  should  not  be  formulated  in
gastro retentive systems.
• Isosorbide dinitrate  are absorbed equally well  throughout  the GI tract  will  not
benefit from incorporation into a gastric retention system.
Limitations of Gastro retentive drug delivery systems [2]:
• Requirement of high levels of fluids in stomach for the delivery system to float
and work efficiently.
• Requires the presence of food to delay gastric emptying.
• Drugs  having  solubility  or  stability  problems  in  the  highly  acidic  gastric
environment  or  which  are  irritants  to  gastric  mucosa  cannot  be  formulated  as
GRDDS.
• In case of bioadhesive systems, the acidic environment, thick mucus as well as
high turnover  rate  of  mucous prevents  bond formation at  the mucous-polymer
interface.
• For  swellable  systems,  the  dosage  form  maintaining  a  size  is  larger  than  the
aperture of the resting pylorus for required time period.
APPROACHES TO GASTRIC RETENTION:
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A number of approaches have been used to increase gastric retention time (GRT) of a
dosage form in stomach by employing a variety of concepts. These include –
a) Floating systems:
Floating Drug Delivery Systems (FDDS) have a bulk density is lower than gastric
fluids and thus remain buoyant in stomach for a prolonged period of time, without
affecting  the  gastric  emptying  rate.  While  the  system  is  floating  on  gastric
contents,  drug  is  released  slowly at  a  desired  rate  from the  system.  After  the
release of drug, the residual system is emptied from the stomach. This result is
increase  in  GRT  and  a  better  control  of  fluctuations  in  plasma  drug
concentrations. Floating systems can be classified into two types, non-effervescent
system and effervescent systems [1].
Figure 2: Classification of Gastro retentive Drug Delivery Systems [2].
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b) Bio/Muco-adhesive Systems [2]:
Bio/muco-adhesive systems are bind to the gastric epithelial cell surface or mucin
and serve  as  a  potential  means of  extending GRT of  drug delivery system in
stomach,  by increasing  the  intimacy  and  duration  of  contact  of  drug  with  the
biological membrane.
Binding  of  polymers  to  mucin/epithelial  surface  can  be  divided  into  three
categories:-
 Hydration-mediated adhesion.
 Bonding-mediated adhesion.
 Receptor-mediated adhesion.
c) Swelling and Expanding Systems [2],[4],[8]:
These are dosage forms, which after swallowing; swell to an extent that prevents
their exit from the pylorus. As a result, the dosage form is retained in stomach for
a long period of time. This system is named as “plug type system”, since they
exhibit tendency to remain logged at the pyloric sphincter.
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d) High Density Systems [1],[2],[3]:
These systems with a density of about 3 g/cm3 are retained in the rugae of stomach
and are capable of withstanding its peristaltic movements. A density of 2.6-2.8
g/cm3 acts as a threshold value after which such systems can be retained in the
lower  parts  of  the  stomach.  High-density  formulations  include  coated  pellets.
Coating  is  done by heavy inert  material  such  as  barium sulphate,  zinc oxide,
titanium dioxide, iron powder etc.
e) Incorporation of Passage Delaying Food Agents [10]:
Food excipients like fatty acids e.g. salts of myristic acid change and modify the
pattern of stomach to a fed state,  thereby decreasing gastric emptying rate and
permitting considerable  prolongation of  release.  The delay in gastric  emptying
after meals rich in fats is largely caused by saturated fatty acids with chain length
of C10-C14.
f) Ion Exchange Resins [11]:
Ion exchange resins are loaded with bicarbonate and a negatively charged drug is
bound to the resin. The resultant beads are then encapsulated in a semi-permeable
membrane to overcome the rapid loss of carbon dioxide. Upon arrival in the acidic
environment of the stomach, an exchange of chloride and bicarbonate ions. As a
result of this reaction carbon dioxide is released and trapped in the membrane
thereby carrying beads towards the top of gastric content and producing a floating
layer of resin beads in contrast to the uncoated beads, sink quickly.
g) Raft Systems [7]:
Incorporated  alginate  gels  that  have a carbonate component  and upon reaction
with gastric acid to give bubbles form in the gel enabling floating.
TYPES OF FLOATING DRUG DELIVERY SYSTEMS (FDDS) [3],[12],[13] 
Based on the mechanism of buoyancy, two distinctly different technologies have been
utilized in development of FDDS which are:
A. Effervescent System and
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B. Non – Effervescent System.
A. Effervescent Systems:
This effervescent systems are prepared with swellable polymers such as Methocel
or  polysaccharides  e.g.,  chitosan  and  effervescent  components,  e.g.  sodium
bicarbonate and citric or tartaric acid or matrices containing chambers of liquid
that gasify at body temperature.
The matrices are fabricated so that upon contact with gastric fluid, carbon dioxide
is  liberated  by  the  acidity  of  gastric  contents  and  is  entrapped  in  the
gelyfiedhydrocolloid. This produces an upward motion of the dosage form and
maintains its buoyancy [3].
The effervescent systems are classified into two types.
I. Gas generating Systems
II. Volatile liquid / Vacuum containing Systems.
I. Gas generating Systems:
1. Intragastric  single  layer  floating  tablets  or  Hydrodynamically  Balanced
System (HBS)
2. Intragastric bilayer floating tablets
3. Multiple unit type floating pills
II. Volatile liquid / Vacuum containing Systems:
1. Intragastric floating Gastrointestinal Drug Delivery System
2. Inflatable Gastrointestinal Delivery System
3. Intragastric Osmotically Controlled Drug Delivery System
B. Non – Effervescent Systems [3],[4]:
Used  gel-forming  or  highly  swellable  cellulose  type  hydrocolloids,
polysaccharides  and  matrix  forming  polymers  such  as  polycarbonate,
polyacrylate, polymethacrylate and polystyrene. One of the approaches to the
formulation of such floating dosage forms involves intimate mixing of drug
with a gel  forming hydrocolloid,  which swells in contact  with gastric fluid
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after oral administration and maintains a relative integrity of shape and a bulk
density of less than unity within the outer gelatinous barrier.
The air entrapped by the swollen polymer confers buoyancy to these dosage
forms. The gel structure acts as a reservoir for sustained drug release as the
drug is slowly released by controlled diffusion through the gelatinous barrier.
Non-effervescent systems include the following:
1. Single layer floating tablets
2. Bilayer floating tablets
3. Alginate Beads
4. Hollow Microspheres
Anatomy and Physiology of Stomach:
The stomach  is  located  in  the  left  upper  part  of  the abdominal  hollow under  the
diaphragm, between the lower end of the oesophagus and the small intestine and is the
most  dilated  part  of  the  GIT [8],[14].  Its  opening  to  the  duodenum is  controlled  by
pyloric sphincter.  The stomach has four main regions namely cardia, fundus, body
and pylorus [14]. Its size varies according to the amount of distention up to 1500 ml
following a meal; after food has emptied, a ‘collapsed’ state is obtained with a resting
volume of only 25-50ml [8].
The two major functions of the stomach are [14]:
• To act as a temporary reservoir for ingested food and to deliver it to the duodenum
at a controlled rate.
• To reduce ingested solids to chyme by the action of acid and enzymatic digestion.
Owing  to  its  small  surface  area  compared  to  the  small  intestine  very  little  drug
absorption occurs in stomach [14]. Storage is the main function of the fundus and body,
whereas mixing and grinding takes place in the antrum. The fundus helps to adjust the
increased volume during eating by relaxing its fundus muscle fibres and also exerts a
steady state  pressure on gastric  content,  pressing them towards distal  stomach. To
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pass through pyloric valve into the small intestine the particle size should be in the
range of 1 to 2mm [4].
Figure 3: Structure of stomach
The stomach has a capacity of approximately 1.5 L, although under fasting conditions
it usually contains no more than 50 ml of fluid, which are mostly gastric secretions.
These include [14]:
• Acid secreted by the parietal cells, which maintains pH of the stomach between
1.0 and 3.5 in fasted state.
• The hormone gastrin, which is a potent stimulator of gastric acid production.
• Pepsin, which is secreted by peptic cells.
• Mucus that is secreted by surface mucosal cells and lines the gastric mucosa. In
the stomach, mucus protects the gastric mucosa from auto digestion by pepsin-
acid combination.
Gastric  volume is  important  for  dissolution of  dosage  form in-vivo.  The resulting
volume of stomach is 25-50ml. gastric pH affects absorption of drugs from CR-DFs.
There is a large volume difference in gastric secretion in normal and achlorohydric
individuals. It affects in-vivo dissolution of drugs when administered with 180 ml of
water. The pH of stomach in fasted condition is about 1.5 – 2.0 and in fed condition is
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2 – 6. The administration of large volume of water with dosage form changes the pH
of stomach to the pH of water initially and this does not improve dissolution of basic
drugs. Generally basic drugs will have a better change to dissolve in fed condition
than in fasted condition [4].
Food buffers and neutralizes gastric acid, thus increasing the pH up to about 6.5. After
meal-ingestion is completed, the pH rapidly falls back to below 5.0 and then gradually
declines to fasting state values over a period of few hours. The pyloric sphincter has a
diameter of 12.8±7 mm in humans and act as a sieve as well as a mechanical stricture
to the passage of large particles [8].
Gastric emptying:
The  time  a  dosage  form takes  to  traverse  the  stomach  is  usually  termed  gastric
emptying  rate.  Gastric  emptying  of  pharmaceuticals  is  highly  variable  and  is
dependent on the dosage form and the fed/fasted state of the stomach. Normal gastric
residence time usually ranges between 5 minutes and 2 hours, although much longer
times (over 12 hours) have been recorded, particularly for large single units [14].
The GI tract is in a state of continuous motility consisting of two modes:
a) Interdigestive motility pattern.
b) Digestive motility pattern
The former is dominant in the fasted state with a primary function of cleaning up the
residual content of upper GIT tract [7].
The fasted state is associated with various cycle events, commonly referred to as the
migrating motor complex (MMC), which regulates GI motility patterns. The MMC is
organized into alternating cycles of activity and quiescence and can be subdivided
into the following phases.
• Phase  I  (Basal  state):-  The  quiescent  period,  lasts  from 30-60  minutes  and  is
characterized by lack of secretory, electrical and contractile activity.
• Phase II (Preburst state):- It exhibits intermittent action for 20-40 minutes during
which  contractile  motions  increase  in  frequency  and  size.  Bile  enters  the
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duodenum during this  phase,  while  gastric  mucus  discharge  occurs  during the
latter part of phase II and throughout phase III.
• Phase  III  (Burst  state):-  It  is  characterized  by  intense  large  and  regular
contractions, termed housekeeper waves, that sweep off undigested food and lasts
10-20 minutes. Maximal pyloric opening, characterizes this phase which enables
efficient evacuation of the stomach contents.
• Phase IV is the transition period of 0-5 minutes between phase III and I [2].
This series of electrical events originates in the foregut and continues to the terminal
ileum in the fasted state repeating every 2-3 hours [2]. Concentration of the hormone
motilin  in  blood  controls  the  duration  of  the  phases.  The  administration  of  food
rapidly interrupts the MMC cycle and the digestive phase is allowed to take place [7].
The motor activity in the fed state is induced 5-10 minutes after ingestion of a meal
and persists as long as food remains in the stomach. The larger the amount of food
ingested, the longer the period of fed activity, with usual time spans of 2-6 hours and
more typically 3-4 hours. The stomach churns food, while suspended fine particles
typically  in  a  size  of  less  than  1mm  are  emptied  through  the  pylorus  into  the
duodenum [8].
The pyloric sphincter allows liquids and small food particles to empty while other
material  is  retropulsed  into the antrum of the stomach and caught  up by the next
peristaltic  wave  for  further  size  reduction  before  emptying.  Thus  in  the  fed  state
liquids,  pellets  and  disintegrated  tablets  will  tend  to  empty  with  food,  yet  large
sustained or controlled release dosage forms can be retained in the stomach for longer
period of time [14].
When CRDDS are administered in fasted state, the MMC in any of its phases, which
can significantly influence total GRT and transit time in the GIT. This assumes even
more significance for drugs that have an absorption window because it is affect the
Department of Pharmaceutics                     J.K.K.M.M.R.F College of Pharmacy
15
Chapter - 1                                                                                                 Introduction
time of dosage form spends in the region preceding and around the window. The less
time spent in that region the lower the degree of absorption. Therefore the design of
GRDDS take into consideration resistance of the dosage form to gastric  emptying
during phase III of MMC in fasted state and continuous gastric emptying through the
pyloric sphincter in the fed state. This means that GRDDS is functional quickly after
administration and able to resist the onslaught of physiological events for the required
period of time [2].
Emptying of DFs from the stomach:
Non-disintegrating DFs, like other indigestible solids are administered in the fasting
state, they typically are not retained in stomach for over 2 hours due to the MMC. On
the other hand in fed condition the GRT of non-disintegrating DFs depends mostly on
the DF size as well as composition and caloric value of food. In general, GRT of DFs
and in particular large DFs is longer in fed state in comparison to fasting state. Large
DFs are retropelled from pyloric antrum for further digestion and evacuation at the
end of fed state or are retained until arrival of the subsequent ‘housekeeper wave’. In
such cases GRT is a function of the length of digestive process. Thus theoretically
continuous feeding can prolong GRT of DF for more than 24 hours [8].
Gastrointestinal Transit Time [4]:
Food contents remain in each segment of the GIT for different periods of time. The
residence time for both liquid and solid foods in each segment of the GIT is reported
as follows:
Table 1: Residence time
Segment Liquid Solid
Stomach
Duodenum
Jejunum and Ileum
10 - 30 min
< 60 sec
3 ± 1.5 hours
-
1 – 3 hours
< 60 sec
4 ± 1.5 hours
20 – 50 hours
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Colon
Quinolone:
The  quinolones  are  a  family  of  synthetic  broad-spectrum  antibiotics.  The  term
quinolone(s) refers to potent synthetic chemotherapeutic antibacterials [15].
The first generation of the quinolones begins with the introduction of nalidixic acid in
1962  for  treatment  of  urinary  tract  infections  in  humans.  Nalidixic  acid  was
discovered  by  George  Lesher  and  coworkers  in  a  distillate  during  an  attempt  at
chloroquine synthesis [16].
Quinolones, in comparison to other antibiotic classes, have the highest risk of causing
colonization  with  Methicillin-resistant  Staphylococcus  aureus  (MRSA)  and
Clostridium  difficile.  For  this  reason,  a  general  avoidance  of  fluoroquinolones  is
recommended based on the available evidence and clinical guidelines. The majority of
quinolones  in  clinical  use  belong  to  the  subset  fluoroquinolones,  which  have  a
fluorine atom attached to the central ring system, typically at the 6-position or C-7
position [17].
Figure 4: Essential structure of all quinolone antibiotics: the blue drawn
remainder of R is usually piperazine; if the connection contains fluorine
(red), it is a fluoroquinolone.
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The newer fluoroquinolones have broad-spectrum bactericidal activity, excellent oral
bioavailability, good tissue penetration and favorable safety and tolerability profiles.
A new four-generation classification of the quinolone drugs takes into account the
expanded antimicrobial  spectrum of the more recently introduced fluoroquinolones
and their clinical indications. 
• First-generation drugs (e.g., nalidixic acid) achieve minimal serum levels.
• Second-generation quinolones (e.g., ciprofloxacin) have increased gram-negative
and systemic activity. 
• Third-generation drugs (e.g., levofloxacin) have expanded activity against gram-
positive bacteria and atypical pathogens. 
• Fourth-generation quinolone drugs (currently only trovafloxacin) add significant
activity against anaerobes. 
The quinolones can be differentiated within classes based on their pharmacokinetic
properties. The new classification can help family physicians prescribe these drugs
appropriately [21].
Classification of Quinolone Antibiotics [21]:
1. First generation
a. Nalidixic acid (NegGram)
b. Cinoxacin (Cinobac)
2. Second generation
a. Norfloxacin (Noroxin)
b. Lomefloxacin (Maxaquin)
c. Enoxacin (Penetrex)
d. Ofloxacin (Floxin)
e. Ciprofloxacin (Cipro)
3. Third generation
a. Levofloxacin (Levaquin)
b. Sparfloxacin (Zagam)
c. Gatifloxacin (Tequin)
d. Moxifloxacin (Avelox)
4. Fourth generation
a. Trovafloxacin (Trovan)
Medical uses:
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Fluoroquinolones are broad spectrum antibiotics that  play an important  role in the
treatment of serious bacterial  infections, especially hospital acquired infections and
others in which resistance to older antibacterial classes is suspected. 
Because the use of broad spectrum antibiotics encourages the spread of multi-drug
resistant  strains  and  the  development  of  Clostridium difficile  infections,  treatment
guidelines from the Infectious Disease Society of America,  the American Thoracic
Society,  and  other  professional  organizations  recommend  minimizing  the  use  of
fluoroquinolones and other broad spectrum antibiotics in less severe infections and in
those in which risk factors for multi-drug resistance are not present.
Adverse effects:
In general, fluoroquinolones are well tolerated, with most side effects being mild to
moderate.  On occasion, serious adverse effects occur. Some of the serious adverse
effects that occur more commonly with fluoroquinolones than with other antibiotic
drug classes include CNS and tendon toxicity. 
The  currently  marketed  quinolones  have  safety  profiles  similar  to  those  of  other
antimicrobial classes. Fluoroquinolones are sometimes associated with a QTc interval
prolongation and cardiac arrhythmias, convulsions, tendon rupture, torsade de pointes
and hypoglycemia. 
These  adverse  reactions  are  a  class  effect  of  all  quinolones;  however,  certain
quinolones are more strongly associated with increased toxicity to certain organs. For
example, moxifloxacin carries a higher risk of QTc prolongation, and gatifloxacin has
been most frequently linked to disturbed blood sugar levels, although all quinolones
carry these risks. 
Some quinolones were withdrawn from the market because of these adverse events
(for example, sparfloxacin was associated with phototoxicity and QTc prolongation,
thrombocytopenia and nephritis were seen with tosufloxacin and hepatotoxicity with
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trovafloxacin). Simultaneous use of corticosteroids is present in almost one-third of
quinolone-associated tendon rupture. The risk of adverse events is further increased if
the dosage is not properly adjusted, for example if there is renal insufficiency.
Contraindications:
Quinolones  are  contraindicated  if  a  patient  has  epilepsy,  QT  prolongation,  pre-
existing CNS lesions, CNS inflammation or those who have suffered a stroke. There
are safeties concerns of fluoroquinolone use during pregnancy and, as a result, are
contraindicated except for when no other safe alternative antibiotic exists. 
However,  one  meta-analysis  looking  at  the  outcome  of  pregnancies  involving
Quinolone use in the first trimester found no increased risk of malformations. They
are also contraindicated in children due to the risks of damage to the musculoskeletal
system. Their use in children is not absolutely contraindicated, however. For certain
severe infections where other antibiotics are not an option, their use can be justified. 
Quinolones should also not be given to people with a known hypersensitivity to the
drug. Quinolone antibiotics should not be administered to patients who are dependent
on benzodiazepines, since they compete directly with benzodiazepines at the GABA-
A receptor, acting as a competitive antagonist and thus possibly precipitating a severe
acute and potentially fatal withdrawal effect.
Pharmacology:
The basic pharmacophore, or active structure, of the fluoroquinolone class is based
upon the quinoline ring system  [18]. The addition of the fluorine atom at C6 is what
distinguishes  the  successive-generation  fluoroquinolones  from  the  first-generation
quinolones. The addition of the C6 fluorine atom has since been demonstrated to not
be required for the antibacterial activity of this class [19].
Various  substitutions  made  to  the  quinoline  ring  resulted  in  the  development  of
numerous fluoroquinolone drugs available today. Each substitution is associated with
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a number of specific adverse reactions, as well as increased activity against bacterial
infections, whereas the quinoline ring, in and of itself, has been associated with severe
and even fatal adverse reactions.
Mechanism of action:
Quinolones and fluoroquinolones are chemotherapeutic bactericidal drugs, eradicating
bacteria by interfering with DNA replication. Quinolones inhibit the bacterial DNA
gyrase  or  the  topoisomerase  II  enzyme,  thereby  inhibiting  DNA  replication  and
transcription. Recent evidence has shown eukaryotic topoisomerase II is also a target
for a variety of quinolone-based drugs [20].
Quinolones inhibit the bacterial DNA gyrase or the topoisomerase II enzyme, thereby
inhibiting DNA replication and transcription. Recent evidence has shown eukaryotic
topoisomerase II is also a target for a variety of quinolone-based drugs. Thus far, most
of  the  compounds  that  show high  activity  against  the  eukaryotic  type  II  enzyme
contain aromatic substituents at their C-7 positions.
Quinolones can enter cells easily via porins and, therefore,  are often used to treat
intracellular  pathogens  such  as  Legionella  pneumophila  and  Mycoplasma
pneumoniae. For many Gram-negative bacteria, DNA gyrase is the target, whereas
topoisomerase IV is the target for many Gram-positive bacteria.  However,  there is
debate concerning whether the quinolones still  have such an adverse effect  on the
DNA of healthy cells,  in the manner described above,  hence  contributing to their
adverse safety profile. This class has been shown to damage mitochondrial DNA.
Mechanism of toxicity:
The  mechanisms  of  the  toxicity  of  fluoroquinolones  has  been  attributed  to  their
interactions  with  different  receptor  complexes  such  as  blockade  of  the  GABAa
receptor  complex  within  the  central  nervous  system,  leading  to  excitotoxic  type
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effects  and  oxidative  stress.  The  severity  of  oxidative  stress  generated  by
fluoroquinolones has been described as 'enormous'  by the authors  of  one research
study  and  they  suggested  co-administration  of  anti-oxidants  when  using
fluoroquinolones to minimise the potential for oxidative related cellular damage.
Interactions:
Theophylline, nonsteroidal anti-inflammatory drugs and corticosteroids enhance the
toxicity of fluoroquinolones.
Products  containing  multivalent  cations,  such  as  aluminium-  or  magnesium-
containing antacids and products containing calcium, iron, or zinc, invariably result in
marked reduction of oral absorption of fluoroquinolones.
Other  drugs  that  interact  with  fluoroquinolones  include  antacids,  sucralfate,
probenecid, cimetidine, warfarin, antiviral agents, phenytoin, cyclosporine, rifampin,
pyrazinamide, andcycloserine.
Many  fluoroquinolones,  especially  ciprofloxacin,  inhibit  the  cytochrome  P450
isoform  CYP1A2.  This  inhibition  causes  an  increased  level  of,  for  example,
antidepressants  such  as  amitriptyline  and  imipramine,  clozapine  (an  atypical
antipsychotic), caffeine, olanzapine (an atypical antipsychotic),  ropivacaine (a local
anaesthetic),  theophylline  (a  xanthine),  and  andzolmitriptan  (a  serotonin  receptor
agonist).
Antibiotic misuse and bacterial resistance:
Resistance  to  quinolones  can  evolve  rapidly,  even  during  a  course  of  treatment.
Numerous  pathogens,  including  Staphylococcus  aureus,  enterococci,  and
Streptococcus  pyogenes  now exhibit  resistance  worldwide.  Widespread  veterinary
usage of quinolones, in particular in Europe, has been implicated.
Fluoroquinolones have been recommended to be reserved for the use in patients that
are seriously ill and may soon require immediate hospitalization. Though considered
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to be very important and necessary drugs required to treat severe and life-threatening
bacterial infections, the associated antibiotic misuse remains unchecked, which has
contributed to the problem of bacterial resistance. The overuse of antibiotics such as
happens with children suffering from otitis media has given rise to a breed of super
bacteria that are resistant to antibiotics entirely.
History:
Nalidixic acid is considered to be the predecessor of all members of the quinolone
family,  including  the  second,  third  and  fourth  generations  commonly  known  as
fluoroquinolones. This first generation also included other quinolone drugs such as
pipemidic acid, oxolinic acid, and cinoxacin, which were introduced in the 1970s. 
They proved to  be only marginal  improvements  over  nalidixic acid.  Though  it  is
generally accepted nalidixic acid is to be considered the first quinolone drug, this has
been disputed over  the years  by a few researchers  who believe chloroquine,  from
which nalidixic acid is derived, is to be considered the first quinolone drug, rather
than nalidixic acid.
Since the introduction of nalidixic acid in 1962, more than 10,000 analogs have been
synthesized, but only a handful have found their way into clinical practice.
Social and economic impact:
Increased  hospitalizations  attributed  to  adverse  drug  reactions  alone  account  for
billions of dollars each year  within the US healthcare system. Severe reactions do
occur with the fluoroquinolone class and can add significantly to the cost of care.
Antibacterial  adverse effects  account  for nearly 25% of all  adverse drug reactions
among hospitalized patients.
Patent extensions:
Under the George W. Bush administration (2001–2009), patent extension legislation
that allowed Bayer AG, as well as other drug companies, a six-month patent extension
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for  testing  their  products  for  safety  in  children  was  signed  into  law.  It  has  been
estimated  that  Bayer  AG's  revenue  increased  an  extra  $358  million  due  to
ciprofloxacin's pediatric patent extension. The legislation was drafted after extensive
lobbying of numerous members of Congress by Bayer AG and others. One of the four
sponsors of this legislation was Chris Dodd (D-CT), who, at the time, ranked as one
of the top three  beneficiaries  of  campaign  contributions  by drug  companies.  Sen.
Edward Kennedy (D-MA), who chaired the committee with jurisdiction over the bill,
refused to fight over the language that (if it had been included) would have reduced
the  drug  company's  profits  due  to  these  patent  extensions.  The  reasons  for  Sen.
Edward Kennedy's decision not to fight for the inclusion of this language were not
made known.
Ciprofloxacin is a synthetic antibiotic of the fluoroquinoline drug class. It is a second-
generation  fluoroquinoline  antibacterial.  It  kills  bacteria  by  interfering  with  the
enzymes that cause DNA to rewind after being copied, which stops synthesis of DNA
and protein [15].
Ciprofloxacin  interacts  with  other  drugs,  herbal  and  natural  supplements,  a
characteristic it shares with other widely used antibacterial drugs such as amoxicillin,
trimethoprim, azithromycin, cephalexin and doxycycline [22].
Medical uses:
Ciprofloxacin is used to treat a number of infections including: infections of bones
and  joints,  endocarditis,  gastroenteritis,  malignant  otitis  externa,  respiratory  tract
infections, cellulitis, urinary tract infections, prostatitis, anthrax, chancroid [23].
Availability:
Ciprofloxacin is available as tablets, intravenous solutions, eye and ear drops.
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Bagherwal et al. [24] (2010) formulated floating tablets of Ciprofloxacin Hcl belong to
the fluoroquinoline derivatives  which is  widely used in the long term therapy for
treatment of a wide range of infections including anthrax, biliary tract infection, bone
and joint infection, gastrointestinal including traveler’s diarrhoea and campylobacter
enteritis,  shiegella,  meningococcal  meningitis  prophylaxis,  surgical  infection
prophylaxis,  tuberculosis,  leprosy and topically in  the treatment  of  eye  infections.
Hence there is a potential need for floating tablet as sustained release dosage form for
this drug. HPMC and carbomer are the polymers, used as suspending agent, viscosity
increasing agent and tablet binder coating agents. In the present study, it was aimed to
formulate floating tablet of ciprofloxacin Hcl with HPMC and carbomer in different
proportion  (4%,  8%  and  12%)  by  direct  compression  techniques  using  polymers
lactose, Magnesium Stearate, talc with sodium bicarbonate. 
Mukhopadhyay  et  al.  [25] (2010)  formulated  floating-bioadhesive  tablets  of
Ciprofloxacin Hcl is  mainly absorbed in the proximal areas of the gastrointestinal
tract thus the purpose of our study was formulation of floating-bioadhesive tablets to
increase the stay period of drug in its absorption area and decrease the dosing interval
by increasing the bioavailability. Floating-bioadhesive tablets were prepared by direct
compression technique using polymer like hydroxy propyl methyl cellulose (HPMC),
sodium  carboxy  methyl  cellulose  (SCMC),  carbopol  in  different  ratios.  The
effervescent base was prepared by using 1:1 ratio of sodium bicarbonate and citric
acid. It was observed that tablet with 5% effervescent base shows greater control in
drug release in comparison to that of 10%.
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Sahoo et  al. [26] (2007) formulated floating microspheres  of  Ciprofloxacin Hcl  by
cross-linking technique. A polymeric mixture of sodium alginate and hydroxy propyl
methyl  cellulose (HPMC) was used. Sodium bicarbonate was used as gas forming
agent.  The solution was dropped to 1% calcium chloride solution containing 10%
acetic  acid  for  carbon  dioxide  release  and  gel  formation.  The  prepared  floating
microspheres  were  evaluated  with  respect  to  particle  size  distribution,  floating
behavior,  drug content, entrapped morphology and in-vitro release study.  Effect of
sodium bicarbonate on the above mentioned parameters were evaluated and it was
found that sodium bicarbonate had a pronounced effect on various parameters.
Danki et al. [27] (2010) studied the development of hydrodynamically balanced system
(HBS) of Alfuzosin Hcl as an anti-hypertensive drug designed to increase the gastric
residence time, thus prolonging the drug release. HPMC of different viscosity grades
to prepared HBS by direct compression technique. The drug polymer ratio, viscosity
grades  of  HPMC,  gas  generating  agents  was  found  to  increase  drug  release  and
floating  property  of  prepared  HBS.  All  HBS  formulation  showed  good  in  vitro
floating property.  It was found that three viscosity grades of HPMC (K4M, K15M,
K100M) HPMC K4M along with lactose as diluents were found to be beneficial in
improving the drug release rate and floating property.
Chandira et al.  [28] (2010)  formulated floating tablets of Itopride hydrochloride,  a
novel prokinetic drug, were developed to prolong the gastric residence time and there
by  increase  drug  bioavailability.  Floating  tablets  were  fabricated;  using  direct
compression  method  containing  Itopride  hydrochloride,  polymers  HPMC K100M,
HPMC  K15M  and  carbopol  934  P,  along  with  gas  generating  agent  sodium
bicarbonate and citric acid. The results found that tablets containing 125 mg HPMC
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K100M, 40 mg HPMC K15M, and 40 mg carbopol provides a better option for 24
hours release action and improved bioavailability 
Rao et al.  [29] (2009)  formulated and optimized the floating drug delivery system of
cephalexin.  Tablets  were  prepared  by  direct  compression  method  incorporating
HPMC K4M, xanthan gum, guar gum, sodium bicarbonate and tartaric acid as gas
generating  agent.  The  diffusion  exponent  of  krosmeyer  -  peppas  for  optimized
formulation was found to be 0.635 which significantly indicated the mechanism of
drug release.  
Bomma et al.  [30] (2009)  prepared floating matrix tablets of norfloxcin which were
developed  to  prolong  gastric  residence  time  leading  to  an  increase  in  drug
bioavailability by using wet  granulation technique using polymers  such as HPMC
K4M,  HPMC  K100M  and  Xanthan  gum.  The  tablets  exhibited  controlled  and
prolonged drug release profile while floating over dissolution medium was confirmed
as drug release mechanism from these tablets.
Thakkar et  al.  [31] (2008)  formulated and evaluated  the levofloxacin  hemihydrate
floating tablets that were prepared by direct compression method using gelucire 43/01
and HPMC polymers in different ratio. The in-vitro release study revealed the fact
that the release rate of drug was decreased by increasing the proportions of gelucire
43/01 by 5 to 40% matrix tablets containing 25% HPMC K4M and 15% gelucire
43/01.
Jaimini et al.  [32] (2007)  formulated and evaluated famotidine floating tablets. They
used Methocel K100 and Methocel K15M with effervescent mixture. It was observed
that decrease in the citric acid level increased the floating lag time but tablets floated
for longer duration. A combination of sodium bicarbonate (130 mg) and citric acid
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(10 mg) was found to achieve optimum in-vitro buoyancy. They reported that tablets
prepared with K100 had longer floating time compared with formulations containing
Methocel K15M.
Ali et al. [33] (2007) formulated hydrodynamically balanced system for metformin as a
single unit floating capsule. The formulation was optimized on the basis of in – vitro
buoyancy and in – vitro release in simulated fed state gastric fluid. Effect of various
release modifiers was studied to ensure the delivery of drug from the HBS capsules
over a prolonged period. Capsules prepared with HPMC K4M and ethyl  cellulose
gave  the  best  in  –  vitro  percentage  release  and  was  taken  as  the  optimized
formulation.
Narendra et al. [34] (2006) reported optimization of bilayer floating tablet containing
metoprolol tartrate as a model drug for gastric retention. They employed a 23 factorial
design  in  formulating  the  GFDDS  with  total  polymer  content-to-drug  ratio  (X1),
polymer-to-polymer  ratio  (X2),  and  different  viscosity  grades  of  HPMC  (X3)  as
independent variables. The results indicate that X1 and X2 – significantly affected the
floating  time and  release  properties  but  the  effect  of  different  viscosity  grades  of
HPMC (K4M and K100M) was non-significant.
Rahman et al. [35] (2006) developed a bilayer-floating tablet (BFT) for captopril using
direct  compression technology.  HPMC, K-grade and effervescent  mixture of citric
acid and sodium bicarbonate formed the floating layer. The release layer contained
captopril and various polymers such as HPMC K15M, PVP-K30 and Carbopol 934p,
alone or in combination with the drug. The floating behavior and in-vitro dissolution
studies were carried out in a USP 23 apparatus 2 in simulated gastric fluid (without
enzyme, pH 1.2). Final formulation released approximately 95% drug in 24 h in-vitro,
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while the floating lag time was 10 min and the tablet remained floatable throughout
all  studies.  Final  formulation  followed  the  higuchi  release  model  and  showed  no
significant  change  in  physical  appearance,  drug  content,  floatability  or  in-vitro
dissolution pattern after storage at 45oC/75% RH for three months.
Srivastava et al.  [36] (2005)  prepared floating matrix tablets of atenolol to prolong
gastric residence time and increase drug bioavailability. The tablets were prepared by
direct compression technique, using polymers such as HPMC K15M, K4M, Guargum
(GG),  and sodium carboxy methylcellulose (SCMC), alone or  in combination and
other  standard  excipients.  Tablets  were  evaluated  for  physical  characteristics  like
hardness, swelling index, floating capacity, thickness and weight variation. The effect
of effervescent on buoyancy and drug release pattern was also studied. In-vitro release
mechanism  was  evaluated  by  linear  regression  analysis.  GG-  and  SCMC-  based
matrix  tablets  showed  significantly  greater  swelling  indices  compared  with  other
batches. The tablets exhibited controlled and prolonged drug release profiles while
floating over the dissolution medium.
Patel et al.  [37] (2005) developed ranitidine floating tablets; in which they optimized
types of filler, different viscosity grades of HPMC and its concentration. Two fillers
namely Avicel pH 102 and Tablettose 80 were used. Study revealed that type of filler
had significant  effect  on release of drug from hydrophilic  matrix tablets (f2 value
41.30)  and  floating  properties.  Three  different  viscosity  grades  of  HPMC namely
K100 LV,  K4M and K15M were  used.  Viscosity  had  a  major  influence  on  drug
release from hydrophilic matrices as well as on floating properties. The drug release
from hydrophilic matrices occurred via diffusion mechanisms following square root
of time profile. Hardness of tablets had greater influence on floating lag time which
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might  be  due  to  decreased  porosity  whereas  the  position  of  paddle  and  types  of
dissolution medium had no significant effect on drug release.
Dave et al.  [38] (2004)  reported a gastroretentive drug delivery system of ranitidine
hydrochloride.  Guar gum, xanthan gum, and hydroxy propyl  methylcellulose were
evaluated for gel forming properties. Sodium bicarbonate was incorporated as a gas-
generating agent. They investigated the effect of citric acid and stearic acid on drug
release  profile  and  floating  properties.  They  concluded  that  the  proper  balance
between a release rate retardant  and a release rate enhancer  could produce a drug
dissolution profile similar to a theoretical dissolution profile.
Amin et al. [39] (2004) developed a gastroretentive drug delivery system of ranitidine
hydrochloride which was designed using guar gum, xanthan gum and HPMC. Sodium
bicarbonate was incorporated as a gas-generating agent. The effect of citric acid and
stearic  acid  on  drug  release  profile  and  floating  properties  was  investigated.  The
addition of stearic acid reduces the drug dissolution due to its hydrophobic nature. A
32 full factorial design was applied to systemically optimize the drug release profile
and the results showed that a low amount of citric acid and a high amount of stearic
acid favor sustained release of ranitidine Hcl from a gastroretentive formulation.
Sangalli et al. [40]  (2004) studied the process parameters and in-vitro performances of
different HPMC viscosity grades as coating agents for an oral time and site controlled
delivery  system.  Methocel  E50  showed  the  best  balance  among  process  time,
retarding ability, dimensions of the coated units and possibility of finely tuning the
delay duration.
Li et al. [41] (2002) evaluated the contribution of formulation variables on the floating
properties  of  a  gastro  floating  drug  delivery  system  using  a  continuous  floating
monitoring device and statistical experimental design. The formulation was conceived
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using  2x3 full  factorial  designs  for  calcium delivery.  HPMC was  used  as  a  low-
density  polymer  and  citric  acid  was  incorporated  for  gas  generation.  Analysis  of
variance (ANOVA) test on the results from these experimental designs demonstrated
that  the  hydrophobic  agent  magnesium  stearate  could  significantly  improve  the
floating capacity of the delivery system. High-viscosity polymers had good effect on
floating properties. The residual floating force values of the different grades of HPMC
were in the order K4 M~ E4 M~K100LV> E5 LV but different polymers with same
viscosity,  i.e.,  HPMC K4M,  HPMC E4M did  not  show any  significant  effect  on
floating property. Better floating was achieved at a higher HPMC/carbopol ratio and
this result demonstrated that carbopol has a negative effect on the floating behavior.
Department of Pharmaceutics                     J.K.K.M.M.R.F College of Pharmacy
34
Chapter - 3                                                                                 Aim and Plan of Work
Aim:
The aim of the present study is to formulation and evaluation of floating tablets of
Ciprofloxacin Hcl using HPMC by direct compression techniques. 
A rationale for developing Ciprofloxacin Hcl as a gastroretentive dosage form, which
is retained in the stomach for prolonged period of time and produces a constant input
of drug to the absorption site. 
This  improves  bioavailability  of  the  drug,  reduces  frequency  of  dosing,  thus
minimizing side effects.
Objective:
Ciprofloxacin is a broad-spectrum antibiotic active against  both Gram-positive and
Gram-negative bacteria. 
It is absorbed completely (91 – 95%) after oral administration and having a biological
half-life of 3 to 5 hrs. The drug should be administered twice a day.
The  objective  of  the  present  study  is  to  formulate  the  Ciprofloxacin  Hcl  floating
tablets  using  HPMC  (K100M,  K4M  and  E50)  in  different  ratio  with  sodium
bicarbonate and lubricants by direct compression techniques.
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Plan of Work:
1. Literature survey
2. Preformulation studies
• Selection of the drug
• Analytical characterization of the drug
• Selection of the excipients
• Characterization of the excipients
3. Standard calibration curve of drug
4. Formulation development
• Formulation of the floating tablet
• Effect  of  the  formulation  variables  on  the  drug  release,  swelling  and
floating properties
5. Evaluation of tablets
• Tablet characteristics
• Floating properties
• Water uptake
• In-vitro drug release studies of tablets
6. Treatment  of  the dissolution data obtained with different  kinetic
release equations
7. Stability study of the optimized batch.
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4.1. MATERIALS AND EQUIPMENTS:
Materials:
Table 2: List of Materials Used
S.No. Materials Manufacturer
1 Ciprofloxacin Hcl Sreepathi Pharmaceuticals Ltd., India.
2 HPMC (K100M, K4M, E50) Taian Ruitai Cellulose Co. Ltd., China.
3 Sodium bicarbonate RFCL Ltd., India.
4 Talc Golcha Group, India.
5 Magnesium stearate Loba Chemie Pvt. Ltd., India.
Equipments:
Table 3: List of Equipments Used
S.No. Equipments Manufacturers
1 Electronic Balance Sartorius, India.
2 UV-VIS Spectrophotometer Shimadzu, Japan.
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3 FTIR Spectrophotometer Shimadzu, Japan.
4 Rotary Tableting Machine Fluidpack, India.
5 Dissolution Test Apparatus Electrolab, India.
6 Vernier Calipers Mitutoyo, Japan.
7 Hardness Test Apparatus Monsanto, India.
8 Friability Test Apparatus Electrolab, India.
4.2. DRUG PROFILE
CIPROFLOXACIN HYDROCHLORIDE [42],[43],[44],[45],[22]:
Ciprofloxacin  Hydrochloride  is  1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-
piperazinyl)-3-quinolinecarboxylic acid hydrochloride monohydrate.
Structure of Ciprofloxacin Hcl:
Empirical Formula:
C17H18FN3O3•HCl•H2O
Molecular Weight: 385.82
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Category: 
Antibacterial
Dose: 
The  equivalent  of  250  to  750  mg  of  ciprofloxacin  twice  daily  (116  mg  of
ciprofloxacin hydrochloride is approximately equivalent to 100 mg of ciprofloxacin).
Description: 
Faintly yellowish to light yellow crystalline substance. 
Solubility: 
Soluble in water; slightly soluble in acetic acid and in methanol; very slightly soluble
in ethanol; practically insoluble in acetone, in acetonitrile, in ethyl acetate, in hexane
and in dichloromethane.
Storage:
Store in tightly-closed, light-resistant containers.
Standards:
Ciprofloxacin Hydrochloride contains not less than 98.0 per cent and not more than
102.0  per  cent  of  C17H18FN3O3,Hcl,  calculated  with  reference  to  the  anhydrous
substance.
Identification: 
A: The infra-red absorption spectrum, Appendix 5.4, is concordant with the reference
spectrum of  ciprofloxacin  hydrochloride  or  with  the  spectrum  obtained
from ciprofloxacin hydrochloride RS.
B: Complies with test B described under Ciprofloxacin using the following solutions
in water containing (1) 1.0% w/v of the substance being examined and (2) 1.0% w/v
of ciprofloxacin hydrochloride RS.
C: Gives the reactions of chlorides, Appendix 3.1.
Procedure:
Dissolve a quantity of the substance being examined equivalent  to about 2 mg of
chloride ion in 2 ml of water or use 2 ml of the prescribed solution. Acidify with
dilute nitric acid, add 0.5 ml of silver nitrate solution, shake and allow to stand, a
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curdy white precipitate is formed, which is insoluble in nitric acid but soluble, after
being well washed with water, in dilute ammonia solution, from which is insoluble in
nitric  acid  but  soluble,  after  being  well  washed  with  water,  in  dilute  ammonia
solution, from which it is reprecipitated by the addition of dilute nitric acid.
pH: 
Between 3.0 and 4.5, determined in a 2.5% w/v solution, Appendix 8.11.
Heavy metals: 
Not more than 20 ppm, determined on 1.0 g by Method B, Appendix 3.12.
Sulphate: 
0.375 g complies with the limit test for sulphates, Appendix 3.15 (400 ppm).
Sulphated ash: 
Not more than 0.1%, Appendix 3.22.
Procedure:
Heat  a  silica  or  platinum crucible  to  redness  for  10  minutes,  allow to  cool  in  a
desiccator  and  weigh.  Unless  otherwise  specified  in  the  individual  monograph,
transfer to the crucible 1 g of the substance being examined and weigh the crucible
and the contents accurately.  Ignite, gently at first, until the substance is thoroughly
charred. Cool, moisten the residue with 1 ml of sulphuric acid, heat gently until the
white fumes are no longer evolved and ignite at 800° ± 25° until all black particles
have disappeared. Conduct the ignition in a place protected from air currents. Allow
the crucible to cool, add a few drops of sulphuric acid and heat. Ignite as before, allow
to cool and weigh. Repeat the operation until two successive weighings do not differ
by more than 0.5 mg.
Water: 
Between 4.7 and 6.7% w/w, determined on 0.2 g, Appendix 3.24.
Assay: 
Carry out the Assay described under Ciprofloxacin using the following solutions in
the  mobile  phase.  Solution  (1)  is  a  0.05%  w/v  solution  of  the  substance  being
examined. Solution (2) contains 0.05% w/v ciprofloxacin hydrochloride RS. Solution
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(3)  contains  0.05%  w/v  each  of ciprofloxacin  ethylenediamine  analog
RS and ciprofloxacin hydrochloride RS.
Calculate  the  content  of  C17H18FN3O3,Hcl  from  the  declared  content  of
C17H18FN3O3,Hcl in ciprofloxacin hydrochloride RS.
Mechanism of action [43]:
Ciprofloxacin is a broad-spectrum antibiotic active against  both Gram-positive and
Gram-negative  bacteria.  It  functions  by  inhibiting  DNA  gyrase,  a  type  II
topoisomerase and topoisomerase IV, enzymes necessary to separate bacterial DNA,
thereby inhibiting cell division.
This  mechanism  can  also  affect  mammalian  cell  replication.  In  particular,  some
congeners of this drug family (for example those that contain the C-8 fluorine) display
high activity not  only against  bacterial  topoisomerases  but also against  eukaryotic
topoisomerases and are toxic to cultured mammalian cells and in vivo tumor models.
Although quinolones are highly toxic to mammalian cells in culture, its mechanism of
cytotoxic action is not known. Quinolone-induced DNA damage was first reported in
1986. 
Recent studies have demonstrated a correlation between mammalian cell cytotoxicity
of the quinolones and the induction of  micronuclei. As such, some fluoroquinolones
may cause injury to the chromosome of eukaryotic cells. 
There  continues  to  be  debate  as  to  whether  or  not  this  DNA  damage  is  to  be
considered one of the mechanisms of action concerning the severe adverse reactions
experienced by some patients following fluoroquinolone therapy.
Clinical Pharmacology [44]:
Absorption:
Ciprofloxacin  given  as  an  oral  tablet  is  rapidly  and  well  absorbed  from  the
gastrointestinal  tract  after  oral  administration.  The  absolute  bioavailability  is
approximately 70% with no substantial loss by first pass metabolism. Ciprofloxacin
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maximum serum concentrations and area under the curve are shown in the chart for
the 250 mg to 1000 mg dose range.
Table 4: Ciprofloxacin dose range of maximum serum concentration and area
under curve
Dose (mg) Maximum SerumConcentration (µg/ml)
Area Under Curve
(AUC) (µg•hr/mL)
250 1.2 4.8
500 2.4 11.6
750 4.3 20.2
1000 5.4 30.8
Maximum serum concentrations  are  attained 1 to 2 hours  after  oral  dosing.  Mean
concentrations 12 hours after dosing with 250, 500, or 750 mg are 0.1, 0.2, and 0.4
µg/ml  respectively.  The serum elimination  half-life  in  subjects  with  normal  renal
function  is  approximately  4  hours.  Serum concentrations  increase  proportionately
with doses up to 1000 mg.
Distribution:
The binding of ciprofloxacin to serum proteins is 20 to 40% which is not likely to be
high enough to cause significant protein binding interactions with other drugs.
After  oral  administration,  ciprofloxacin  is  widely distributed throughout  the body.
Tissue concentrations often exceed serum concentrations in both men and women,
particularly in genital tissue including the prostate. 
Ciprofloxacin is present in active form in the saliva, nasal and bronchial secretions,
mucosa of the sinuses, sputum, skin blister fluid, lymph, peritoneal fluid, bile, and
prostatic secretions. 
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Ciprofloxacin has also been detected in lung, skin, fat, muscle, cartilage, and bone.
The drug diffuses into the cerebrospinal fluid (CSF); however, CSF concentrations are
generally less than 10% of peak serum concentrations. Low levels of the drug have
been detected in the aqueous and vitreous humors of the eye.
Metabolism:
Four  metabolites  have  been  identified  in  human urine which  together  account  for
approximately 15% of an oral dose. The metabolites have antimicrobial activity, but
are less active than unchanged ciprofloxacin.
Excretion:
The  serum  elimination  half-life  in  subjects  with  normal  renal  function  is
approximately 4 hours. Approximately 40 to 50% of an orally administered dose is
excreted  in  the  urine  as  unchanged  drug.  After  a  250  mg  oral  dose,  urine
concentrations of ciprofloxacin usually exceed 200 µg/ml during the first two hours
and are approximately 30 µg/ml at 8 to 12 hours after dosing. 
The urinary excretion  of  ciprofloxacin is  virtually complete within 24 hours  after
dosing. The renal clearance of ciprofloxacin, which is approximately 300 ml/minute,
exceeds the normal glomerular filtration rate of 120 ml/minute. Thus, active tubular
secretion would seem to play a significant role in its elimination.
Adverse Effects [45]:
The serious adverse effects that may occur as a result of ciprofloxacin therapy include
irreversible peripheral neuropathy, spontaneous tendon rupture and tendonitis, acute
liver failure or serious liver injury (hepatitis), toxic epidermal necrolysis (TEN), and
Stevens–Johnson  syndrome,  severe  central  nervous  system  disorders  (CNS)  and
Clostridium difficile associated disease (CDAD: pseudomembranous colitis), as well
as photosensitivity/phototoxicity reactions.
Interactions [22]:
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The  toxicity  of  drugs  that  are  metabolised  by  the  cytochrome  P450  system  is
enhanced by concomitant use of some quinolones. Quercetin, a flavonol, occasionally
used  as  a  dietary  supplement,  may  interact  with  fluoroquinolones,  as  quercetin
competitively binds  to  bacterial  DNA gyrase.  Ciprofloxacin  can  reduce  phenytoin
plasma  levels,  which  may,  in  some  cases,  result  in  seizures.  Ciprofloxacin  may
interfere with the levels of thyroid medications resulting in hypothyroidism.
Coadministration  of  ciprofloxacin  with  other  drugs  primarily  metabolized  by
CYP1A2 results in increased plasma concentrations of these drugs and could lead to
clinically significant adverse events of the coadministered drug. 
Concurrent  administration of ciprofloxacin with  magnesium or  aluminum antacids,
sucralfate or  products  containing calcium, iron,  or zinc(including  multivitamins  or
other dietary supplements) may substantially decrease the absorption of ciprofloxacin,
resulting in serum and urine levels considerably lower than desired. 
Precautions [44]:
General:-
Crystals of ciprofloxacin have been observed rarely in the urine of human subjects but
more  frequently  in  the  urine  of  laboratory  animals,  which  is  usually  alkaline.
Crystalluria related to ciprofloxacin has been reported only rarely in humans because
human urine is usually acidic. Alkalinity of the urine should be avoided in patients
receiving ciprofloxacin. 
Central Nervous System:-
Quinolones, including ciprofloxacin, may also cause central nervous system (CNS)
events, including: nervousness, agitation, insomnia, anxiety, nightmares or paranoia.
Renal Impairment:-
Alteration of the dosage regimen is necessary for patients with impairment of renal
function. 
Contraindications [44]:
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Ciprofloxacin  is  contraindicated  in  persons  with  a  history  of  hypersensitivity  to
ciprofloxacin, any member of the quinolone class of antimicrobial agents, or any of
the product components.There are only four contraindications found within the 2009
package insert: 
 Coadministration  of  ciprofloxacin  with  other  drugs  primarily  metabolized
by CYP1A2 results in increased plasma concentrations of these drugs and could
lead to clinically significant adverse events of the coadministered drug.
 Concomitant administration with tizanidine is contraindicated.
 Ciprofloxacin is contraindicated in persons with a history of hypersensitivity
to ciprofloxacin, any member of the quinolone class of antimicrobial agents, or
any of the product components.
 Local I.V. site reactions are more frequent if the infusion time is 30 minutes or
less.  These  may  appear  as  local  skin  reactions  that  resolve  rapidly  upon
completion  of  the  infusion.  Subsequent  intravenous  administration  is  not
contraindicated unless the reactions recur or worsen.
Overdose [45]:
Overdose  of  ciprofloxacin  may  result  in  reversible  renal  toxicity.  Treatment  of
overdose includes emptying of the stomach via induced vomiting or by gastric lavage.
Administration of magnesium, aluminum or calcium containing antacids can reduce
the absorption of ciprofloxacin. Hemodialysis or peritoneal dialysis removes only less
than  10  percent  of  ciprofloxacin. Ciprofloxacin  may  be  quantitated  in  plasma  or
serum to monitor for drug accumulation in patients with hepatic dysfunction or to
confirm a diagnosis of poisoning in acute overdose victims. 
4.3. POLYMER PROFILE
HYDROXYPROPYL METHYL CELLULOSE [46]:
Non-proprietory Names:
BP: Hypromellose
USP: Hydroxypropyl methyl cellulose 2208, 2906, 2910
Synonyms:
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Methyl hydroxypropyl cellulose, Methocel, Methyl cellulose propylene glycol ether.
Chemical Name and CAS Registry Number:
Cellulose Hydroxypropylmethyl ether [9004–65–3]
Molecular weight:
Approximately 10,000 to 15,00,000
Structural formula:
Where R is H, CH3, or CH3CH(OH)CH2
Functional Category:
Bioadhesive  material;  coating  agent;  controlled-release  agent;  dispersing  agent;
dissolution enhancer; emulsifying agent; emulsion stabilizer; extended-release agent;
film-forming  agent;  foaming  agent;  granulation  aid;  modified-release  agent;
mucoadhesive;  release-modifying  agent;  solubilizing  agent;  stabilizing  agent;
suspending agent; sustained-release agent; tablet binder; thickening agent; viscosity-
increasing agent.
Applications in Pharmaceutical Formulation:
Hypromellose is widely used in oral, ophthalmic, nasal, and topical pharmaceutical
formulations. 
In oral products, hypromellose is primarily used as a tablet binder, in film-coating,
and  as  a  matrix  for  use  in  extended  release  tablet  formulations.  Concentrations
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between 2% and 5% w/w may be used as a binder in either wet- or dry-granulation
processes. 
High-viscosity grades may be used to retard the release of drugs from a matrix at
levels of 10–80% w/w in tablets and capsules. Hypromellose is also used in liquid
oral dosage forms as a suspending and/or thickening agent at concentrations ranging
from 0.25–5.0%.
Hypromellose  is  also  used  as  a  suspending  and  thickening  agent  in  topical
formulations.  Compared  with  methylcellulose,  hypromellose  produces  aqueous
solutions of greater clarity,  with fewer undissolved fibers  present,  and is therefore
preferred in formulations for ophthalmic use. 
Hypromellose  at  concentrations  between  0.45–1.0%  w/w  may  be  added  as  a
thickening agent to vehicles for eye drops and artificial tear solutions. It is also used
commercially in liquid nasal formulations at a concentration of 0.1%.
Hypromellose  is  used as an emulsifier,  suspending agent,  and  stabilizing agent  in
topical  gels  and  ointments.  As  a  protective  colloid,  it  can  prevent  droplets  and
particles  from  coalescing  or  agglomerating,  thus  inhibiting  the  formation  of
sediments. 
Description:
An odorless and tasteless, white or creamy-white fibrous or granular powder.
Solubility:
Soluble in cold water, forming a viscous colloidal solution; practically insoluble in
hot water, chloroform, ethanol (95%) and ether.
Acidity/alkalinity: 
pH = 5.0–8.0 for a 2% w/w aqueous solution.
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Viscosity:
HPMC K100M: 1,00,000 mPa-s
HPMC K4M: 4,000 mPa-s
HPMC E50: 50 mPa-s
Stability and Storage Conditions:
Very stable in dry conditions. Solutions are stable at pH 3.0 – 11.0. Stored in a well
closed container, in a cool, dry place.
Incompatibilities:
Hypromellose  is  incompatible  with  some  oxidizing  agents.  Since  it  is  nonionic,
hypromellose will not complex with metallic salts or ionic organics to form insoluble
precipitates.
Method of Manufacture:
A purified form of cellulose, obtained from cotton linters or wood pulp, is reacted
with sodium hydroxide solution to produce swollen alkali cellulose that is chemically
more reactive than untreated cellulose. 
The  alkali  cellulose  is  then  treated  with  chloromethane  and  propylene  oxide  to
produce methyl  hydroxypropyl  ethers  of cellulose.  The fibrous reaction product is
then purified and ground to a fine, uniform powder or granules. 
Handling Precautions:
Observe normal precautions appropriate to the circumstances and quantity of material
handled.  Hypromellose  dust  may  be  irritating  to  the  eyes,  so  eye  protection  is
recommended. Excessive dust generation should be avoided to minimize the risks of
explosion. Hypromellose is combustible. 
Regulatory Status: 
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA
Inactive  Ingredients  Database  (ophthalmic  and  nasal  preparations;  oral  capsules,
suspensions,  syrups,  and  tablets;  topical  and  vaginal  preparations).  Included  in
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nonparenteral  medicines  licensed  in  the  UK.  Included  in  the  Canadian  List  of
Acceptable Non-medicinal Ingredients. 
4.4. EXCIPIENT PROFILE
SODIUM BICARBONATE [46]:
Functional Category:
USP: Alkalizing agent
BP: Antacid; systemic alkalinizing substance
Synonyms:
Sodium hydrogen carbonate, sodium acid carbonate, baking soda
Chemical Name and CAS Registry Number:
Carbonic acid monosodium salt [144-55-8]
Empirical Formula: NaHCO3
Molecular weight: 84.01
Applications in Pharmaceutical Formulation:
Sodium bicarbonate is generally used in pharmaceutical formulations as a source of
carbon dioxide in effervescent tablets and granules. It is also widely used to produce
or maintain an alkaline pH in a preparation.
Tablets may also be prepared with sodium bicarbonate alone since the acid of gastric
fluid is sufficient to cause effervescence and disintegration. Sodium bicarbonate is
also used in tablet formulations to buffer drug molecules that are weak acids, thereby
increasing the rate of tablet dissolution and reducing gastric irritation.
Additionally,  sodium  bicarbonate  is  used  in  solutions  as  a  buffering  agent  for
erythromycin,  lidocaine,  local  anesthetic  solutions,  and  total  parenteral  nutrition
(TPN) solutions. In some parenteral formulations, e.g. niacin, sodium bicarbonate is
used to produce a sodium salt of the active ingredient that has enhanced solubility.
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Sodium  bicarbonate  has  also  been  used  as  a  freeze-drying  stabilizer  and  in
toothpastes.
Recently, sodium bicarbonate has been used as a gas-forming agent in alginate raft
systems and in floating, controlled release oral dosage forms for a range of drugs.
Tablet formulations containing sodium bicarbonate have been shown to increase the
absorption  of  paracetamol,  and  improve  the  stability  of  levothyroxine.  Sodium
bicarbonate has also been included in formulations of vaginal bioadhesive tablets and
in carbon dioxide releasing suppositories.
Therapeutically, sodium bicarbonate may be used as an antacid, and as a source of the
bicarbonate anion in the treatment of metabolic acidosis.  Sodium bicarbonate may
also be used as a component of oral rehydration salts and as a source of bicarbonate in
dialysis  fluids;  it  has also been suggested as a means of preventing radiocontrast-
induced nephrotoxicity. Sodium bicarbonate is used in food products as an alkali or as
a leavening agent, e.g. baking soda.
Table 5: Uses of sodium bicarbonate
Use Concentration (%)
Buffer in tablets 10–40
Effervescent tablets 25–50
Isotonic injection/infusion 1.39
Description:
An  odorless,  white  crystalline  powder  with  a  slightly  alkaline  taste. The  crystal
structure  is  monoclinic  prisms.  Grades  with  different  particle  sizes,  from  a  fine
powder to free-flowing uniform granules, are commercially available.
Acidity/alkalinity:
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pH = 8.3 for a freshly prepared 0.1Maqueous solution at 258C; alkalinity increases on
standing, agitation, or heating.
Solubility: 
Water:  1 part  in 11 parts (20oC), 1 part  in 4 parts (100oC), Ethanol (95%; 20oC):
insoluble; Ether (20oC): practically insoluble.
Melting point: 
270oC with decomposition.
Hygroscopicity: 
At relative humidities below 80%, the moisture content is less than 1%. Above 85%
relative  humidity,  it  rapidly absorbs  excessive amounts  of  water  and may start  to
decompose.
Stability and Storage Conditions:
Upon heating at 250oC to 300oC, sodium bicarbonate decomposes and is converted
into anhydrous sodium carbonate. Sodium bicarbonate is stable in dry air but slowly
decomposes in moist air and should therefore be stored in a well-closed container in a
cool, dry place.
Incompatibilities:
Sodium bicarbonate reacts with acids, acidic salts and many alkaloidal salts, with the
evolution  of  carbon  dioxide.  It  can  also  intensify  the  darkening  of  salicylates.  In
powder  mixtures,  atmospheric  moisture  or  water  of  crystallization  from  another
ingredient is sufficient for sodium bicarbonate to react with compounds such as boric
acid or alum.
Method of Manufacture:
Sodium bicarbonate  is  manufactured  either  by passing carbon  dioxide into a  cold
saturated solution of sodium carbonate, or by the ammonia–soda (Solvay) process, in
which  first  ammonia  and  then  carbon  dioxide  is  passed  into  a  sodium  chloride
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solution to precipitate sodium bicarbonate while the more soluble ammonium chloride
remains in solution.
Handling Precautions:
Observe normal precautions appropriate to the circumstances and quantity of material
handled. Eye protection and gloves are recommended.
Regulatory Status:
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA
Inactive  Ingredients  Database  (injections;  ophthalmic  preparations;  oral  capsules,
solutions, and tablets). Included in parenteral (intravenous infusions and injections)
and nonparenteral  medicines (chewing gums; ear drops; eye  lotions; oral  capsules,
chewable tablets, effervescent powders, effervescent tablets, granules, soluble tablets,
orodispersible tablets, and tablets; suppositories and suspensions) licensed in the UK.
 
TALC [46]:
Non-proprietory Names:
BP: Purified Talc
USP: Talc
Synonyms:
Hydrous  magnesium calcium  silicate;  Hydrous  magnesium  silicate;  Magnesium
hydrogen metasilicate; Powdered talc; Talcum.
Chemical Name and CAS Registry Number:
Talc [14807-96-6]
Empirical Formula:
Mg6(Si2O5)4(OH)4
Functional Category:
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant.
Applications in Pharmaceutical Formulation:
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Talc  was  once  widely  used  in  oral  solid  dosage  formulations  as  a  lubricant  and
diluent, although today it is less commonly used. However,  it  is  widely used as a
dissolution retardant in the development of controlled-release products. 
Talc is also used as a lubricant in tablet formulations; in a novel powder coating for
extended-release  pellets;  and  as  an  adsorbant.  Talc  is  a  natural  material;  it  may
therefore frequently contain microorganisms and should be sterilized when used as a
dusting powder.
Talc is additionally used to clarify liquids and is  also used in cosmetics and food
products, mainly for its lubricant properties.
Table 6: Uses of talc
Use Concentration (%)
Dusting powder 90.0–99.0
Glidant and tablet lubricant 1.0–10.0
Tablet and capsule diluent 5.0–30.0
Description:
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline
powder. It adheres readily to the skin and is soft to the touch and free from grittiness.
Acidity/alkalinity:
pH = 7–10 for a 20% w/v aqueous dispersion.
Solubility: 
Practically insoluble in dilute acids and alkalis, organic solvents, and water.
Stability and Storage Conditions:
Talc is a stable material and may be sterilized by heating at 1608C for not less than 1
hour. Stored in a well-closed container in a cool, dry place.
Incompatibilities:
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Incompatible with quaternary ammonium compounds.
MAGNESIUM STEARATE [46]:
Synonyms:
Dibasic  magnesium  stearate;  Magnesium  distearate;  Magnesium  octadecanoate;
Octadecanoic acid magnesium salt; Stearic acid magnesium salt.
Chemical Name and CAS Registry Number:
Octadecanoic acid magnesium salt [557-04-0]
Empirical Formula: C36H70MgO4 
Molecular weight: 591.24
Functional Category:
Tablet and capsule lubricant.
Applications in Pharmaceutical Formulation:
Magnesium  stearate  is  widely  used  in  cosmetics,  foods,  and  pharmaceutical
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.
Description:
Magnesium stearate  is  a  very  fine,  light  white,  impalpable  powder,  faint  odor  of
stearic acid. The powder is greasy to the touch and readily adheres to the skin.
Solubility: 
Practically  insoluble  in  ethanol  (95%),  ether  and  water;  slightly  soluble  in  warm
benzene and warm ethanol (95%).
Stability and Storage Conditions:
Magnesium stearate is stable and should be stored in a well-closed container in a cool,
dry place.
Incompatibilities:
Incompatible  with  strong  acids,  alkalis,  and  iron  salts.  Avoid  mixing with strong
oxidizing  materials.  Magnesium  stearate  cannot  be  used  in  products  containing
aspirin, some vitamins, and most alkaloidal salts.
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Method of Manufacture:
Magnesium stearate  is  prepared  either  by  the  interaction  of  aqueous  solutions  of
magnesium chloride with sodium stearate or by the interaction of magnesium oxide,
hydroxide, or carbonate with stearic acid at elevated temperatures.
Handling Precautions:
Observe normal precautions appropriate to the circumstances and quantity of material
handled.  Eye  protection  and  gloves  are  recommended.  Excessive  inhalation  of
magnesium stearate dust may cause upper respiratory tract discomfort, coughing, and
choking. Magnesium stearate should be handled in a well-ventilated environment; a
respirator is recommended.
Regulatory Acceptance:
GRAS listed. Accepted as a food additive in the USA and UK. Included in the FDA
Inactive Ingredients Database (oral capsules, powders, and tablets; buccal and vaginal
tablets; topical preparations; intravitreal implants and injections). 
4.5. PREFORMULATION STUDIES [42],[47]:
It is one of the important prerequisite in development of any drug delivery system.
Preformulation  studies  were  performed  on  the  drug,  which  included  description,
solubility, pH, and compatibility studies.
a) Description:
Description of Ciprofloxacin Hcl was determined.
b) Solubility:
Solubility  of  Ciprofloxacin  Hcl  in  water,  0.1N  Hcl,  acetone,  acetonitrile  and
dichloromethane.
c) pH:
pH of Ciprofloxacin Hcl was determined to IP studies. Between 3 to 4.5 in a 2.5%
w/v solution.
d) Compatibility Studies:
Department of Pharmaceutics                     J.K.K.M.M.R.F College of Pharmacy
55
Chapter - 4                                                                               Materials  and Methods
The compatibility of the drug and polymer under experimental conditions is an
important prerequisite before formulation. It is necessary to confirm that the drug
does not react with the polymer and affect the shelf life of the product. This can be
confirmed by carrying out infrared spectroscopy studies.
Procedure: The obtained drug and polymer were subjected to IP studies. In the
present  study  potassium  bromide  disc  (pellet)  method  was  employed  and  the
obtained  IR  spectra  were  analysed  comparatively,  with  reference  spectrum of
Ciprofloxacin Hcl.
 
4.6. METHODOLOGY [24]:
Floating tablets of Ciprofloxacin Hcl were prepared by direct compression technique
using varying ratio of polymer such as HPMC (K100M, K4M and E50) with sodium
bicarbonate as gas generating agent. The composition of each formulation is given in
Table 7. The formulated tablets are given in Figure 5.
HPMC (K100M, K4M and E50) ratio used in the formulations F1 is 1:2:3, F2 is 1:3:2,
F3 is 1:1:1, F4 is 2:1:3, F5 is 2:3:1, F6 is 3:1:2 and F7 is 3:2:1. 
Sifting:
Ciprofloxacin  Hcl  was  passed  through  sieve  no.  20  and  collect  in  a  clean  bowl.
HPMC  K100M,  HPMC  K4M,  HPMC  E50  and  sodium  bicarbonate  were  passed
through sieve no. 40 and collect in a clean bowl. Talc was passed through sieve no. 60
and collect  in a clean bowl. Finally magnesium stearate was passed through sieve
no.60 and collect in a separate clean bowl. 
Mixing:
Ciprofloxacin Hcl was geometrical mixed with HPMC K100M, HPMC K4M, HPMC
E50 and sodium bicarbonate for 10 minutes. Then talc was added and further mixed
for 5 minutes.
Lubrication:
After sufficient mixing of drug as well as other component, magnesium stearate was
added and further mixed for additional 2 minutes. 
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Compression:
The lubricated granules were compressed by Rotary tableting machine. The weight of
the tablet was kept constant for all formulations.
Table 7: Composition of Ciprofloxacin floating tablets 
Ingredients
(mg/tablet)
Batch Code
F1 F2 F3 F4 F5 F6 F7
Ciprofloxacin Hcl 500 500 500 500 500 500 500
HPMC K100M 20 20 40 40 40 60 60
HPMC K4M 40 60 40 20 60 20 40
HPMC E50 60 40 40 60 20 40 20
Sodium bicarbonate 100 100 100 100 100 100 100
Talc 5 5 5 5 5 5 5
Magnesium stearate 5 5 5 5 5 5 5
Total 730 730 730 730 730 730 730
Figure 5: Formulated tablets of Ciprofloxacin floating tablets
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4.7. EVALUATION PARAMETERS:
A) Pre-Compression Parameters [48]:
i) Bulk Density: 
Both loose bulk density (LBD) and tapped bulk density (TBD) were determined.
Accurately weighted amount of sample (5 gm) was transferred into a  25 ml
measuring  cylinder.  The  volume  of  packing  was  recorded.  The  measuring
cylinder  was then tapped 100 times on a plane hard wooden surface and the
tapped volume of packing was recorded. LBD and TBD were calculated by the
following formula:
LBD (Loose bulk density) = Weight of granules
       Volume of packing
TBD (Tapped bulk density) = Weight of granules
    Tapped volume of packing
                 
ii) Compressibility Index: 
Percent  compressibility  of  granules  as  determined  by  Carr’s  compressibility
index was calculated by the following formula:
Carr’s Index = TBD – LBD      x   100
               TBD
iii) Hausner Ratio: 
Hauser ratio was calculated by the following formula:
Hausner ratio = TBD     
           LBD
iv) Angle of Repose (θ): 
The frictional forces in a loose powder or granules can be measured by angle of
repose.  This is the maximum angle possible between the surface of a pile of
powder or granules and the horizontal plane.
The granules were allowed to flow through the funnel fixed to a stand at definite
height (h). The angle of repose was then calculated by measuring the height and
radius of the heap of granules formed.
tan θ = h/r
θ = tan-1 (h/r)
Where θ = Angle of repose
           h = height of the heap
           r = radius of the heap
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Table 8: Scale of flow property
Flow property Angle of Repose(θ in  degrees)
Compressibility
Index ( CI in % ) Hausner Ratio
Excellent 25 – 30 < 10 1.00 – 1.11
Good 31 – 35 11 -  15 1.12 – 1.18
Fair 36 – 40 16 – 201.19 – 1.25
Possible 41 – 45 21 -  25 1.26 – 1.34
Poor 46 – 55 26 – 31 1.35 – 1.45
Very Poor 56 – 65 32 – 37 1.46 – 1.59
Very, very poor >  66 > 38 > 1.60
B) Post-Compression Parameters:
The tablets were evaluated for the various parameters enlisted below:-
1. Appearance
2. Weight variation
3. Thickness
4. Hardness
5. Friability
6. Drug content
7. Tablet density
8. Floating test
9. Swelling study
10. In-vitro dissolution studies
11. Kinetics of drug release
12. Stability studies
1) Appearance: 
The  compressed  tablets  were  examined  under  the  magnifying  lens  for  its
appearance.
2) Weight Variation:
The  procedure  described  in  IP  1996  was  employed  to  determine  the  weight
variation of the tablets. Ten tablets were randomly selected from each batch and
weighed  to  determine  the  average  weight  and  were  compared  with  individual
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tablet weight. The percentage deviation was calculated and checked for weight
variation [49].
Table 9: Percentage deviation of Average weight
3) Thickness: 
The tablet thickness is essential for consumer acceptance and to maintain tablet to
tablet uniformity. The thickness of the tablets was measured using vernier caliper.
It  is  expressed  in  mm. 5  tablets  of  each  batch  were  picked  randomly  and  its
thickness were measured individually. The thickness of the tablet is mostly related
to the tablet hardness [48].
4) Hardness: 
Hardness indicates the ability of a tablet to withstand mechanical  shocks while
handling. The hardness of the tablets was determined using Mansanto hardness
tester.  It  is expressed in kg/cm2.  Five tablets were randomly picked from each
batch and the hardness of the tablets was determined.
5) Friability: 
Friability of the tablets was determined using Roche friabilator. It is expressed in
percentage (%). Ten tablets were initially weighed (Winitial) and placed into the
friabilator. The friabilator was operated at 25 rpm for 4 minutes or run up to 100
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revolutions, and then the tablets were weighed again (Wfinal). The loss in tablet
weight due to abrasion or fracture was the measure of tablet friability.
% Friability was then calculated by:-
F = W(initial) – W(final)     x    100
        W(initial)
% Friability of less than 1% is considered acceptable.
6) Drug Content: 
Ten tablets from each batch were weighed and powdered. Powder equivalent to
the average weight of the tablet was accurately weighed in a 100 ml volumetric
flask and dissolved in a suitable quantity of 0.1 N Hcl. Then the volume was made
upto 100ml with 0.1 N Hcl and filtered. 2 ml of filtrate was transferred to a 100 ml
volumetric flask and volume was made with 0.1 N Hcl. The absorbance of the
resulting solution is measured by UV spectrophotometer at 276nm.
7) Tablet Density [50]: 
Tablet density is an important parameter for floating tablets. The tablet will only
float when its density is less than that of gastric fluid (1.004 g/cm3). The density
was determined using following relationship.
V = lbh
d = m/V
V = volume of tablet (cc)
 l = length of tablet (cm)
b = width of tablet (cm)
h = crown thickness of tablet (cm)
m = mass of tablet (g)
d = density of tablet (g/cc)
8) Floating Test [38]: 
The  tablets  were  placed  in  a  100  ml  beaker  containing  0.1  N  Hcl.  The  time
between introduction of dosage form and its buoyancy on 0.1 N Hcl, and the time
during which the dosage form remains buoyant were measured. The time taken for
the dosage form to emerge on surface of medium is called Floating Lag Time
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(FLT) or Buoyancy Lag Time (BLT) and total duration of time during which the
dosage form remains buoyant is called Total Floating Time (TFT).
9) Swelling Study [2]: 
The swelling behavior of a dosage form is measured by studying its weight gain or
water uptake (WU). The study was done by immersing the dosage form in 0.1 N
Hcl at 37oC and determining these factors at regular intervals up to a period of 8
hours. Water uptake was measured in terms of percent weight gain, as given by
the equation.
WU = (Wt – Wo) x 100 / Wo
Wt  = Weight of the dosage form at time t.
Wo = Initial weight of the dosage form.
10) In-vitro Dissolution Studies:
Standard calibration curve [42]:
Weighed  accurately  100  mg of  Ciprofloxacin  Hcl  and  dissolved  in  a  suitable
quantity of 0.1 N Hcl in a 100ml volumetric flask. Then the volume was made
upto 100ml with 0.1 N Hcl, which gives 1000 µg/ml concentration.
The standard stock solution was then serially diluted with 0.1 N Hcl to get 5, 10,
15, 20, 25 and 30 µg/ml of Ciprofloxacin Hcl. The absorbance of the solutions
was measured against 0.1 N Hcl as blank at 276 nm using spectrophotometer. The
absorbance  values  were  plotted  against  concentration  (µg/ml)  to  obtain  the
standard calibration curve.
Cumulative % drug release:
In-vitro drug release profile of Ciprofloxacin Hcl was evaluated using (paddle,
900 ml 0.1 N Hcl, 37±0.5oC, 50 rpm). One tablet was placed in each of the six
dissolution vessels and the system was run.
Aliquots of samples were withdrawn after 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th and 10th
hour. Fresh dissolution medium was replaced to maintain the original volume. The
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withdrawn  aliquots  were  filtered,  suitably  diluted  with  0.1  N  Hcl  to  obtain
concentration of 10µg/ml, and its absorbance measured spectrophotometrically at
276 nm to determine drug release.
11) Kinetics of Drug Release [51]:
The  data  obtained  from in-vitro  dissolution  studies  was  subjected  in  order  to
determine release kinetics of the formulations.
Zero order kinetics: 
Drug dissolution from pharmaceutical dosage from that do not disaggregate and
release the drug slowly (assuming that area does not change and no equilibrium
conditions are obtained) can be represented by the following equation.
W0 –Wt = Kt --------- (1)
Where, W0 = initial amount of drug in the pharmaceutical dosage form,
            Wt = amount of drug in the pharmaceutical dosage form,
       t =    time,
       K = Proportionality constant.
The pharmaceutical dosage form following this profile release the same amount of
drug by unit of time and in this model can be explained by following equation:
Qt = Q0 + K0t ---------------- (2)
Where, Qt = Cumulative amount of drug release at time "t", 
             Q0 = Initial amount of drug in solution,
             K0 = Zero order rate constant.
             t = time in hours.
OR,
W = K.t ----------------- (3)
Where W is percentage drug release at time t, 
      K is the release rate constant.
It  describes  the  systems  where  the  drug  release  rate  is  independent  of  its
concentration of the dissolved substance.
A graph is plotted between the time taken on x-axis and the cumulative % of drug
release on y-axis and it gives a straight line.
First order kinetics: 
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The application of this model to drug dissolution studies was first proposed by
Gibaldi and Feldman (1967) and later by Wagner.  The dissolution phenomena
implies a surface action, as can be seen by Noyes – Whitney equation,
)( CCK
dt
dc
s −=  ----------- (4)
Where, C = Concentration of solute in time t,
             CS = solubility in equilibrium at experience temperature.
             k =First order proportionality constant
Hixson and Crowell adapted the above equation as 
)( CCKS
dt
Dw
s −=  ------------- (5)
Where, w = amount of solute in solution at time t,
             S = Solid area accessible to dissolution.
log Qt = log Q0 + K1.t / 2.303 --------- (6)
Where, Qt = amount of drug release in time t, 
             Q0 = initial amount of drug in solution,
        K1 = First order release constant.
Above equation also represents this model.
The pharmaceutical dosage form following this dissolution profile, such as those
containing water soluble drugs in porous matrices release drug in a way that is
proportional  to  amount  of  drug  remaining  in  its  interior  in  such  a  way  that
amount of drug released by unit of time diminish.
OR, In (100 – W) = In 100 – k t ---------- (7)
Here, the drug release rate depends on  its concentration.
A graph is plotted between the time taken on x-axis and the log cumulative % of
drug remaining to be  released on y-axis and it gives a straight line.
Higuchi Model / Higuchi’s square Root of time Equation 
(Diffusion model): 
Higuchi developed mathematical expressions for drugs particles dispersed in a
uniform matrix  behaving as diffusion media.  To study the dissolution form a
planar system having a homogeneous matrix, the relation obtained was
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tCCCQft SS )2( −==  -------------- (8)
Where, Q = Amount of drug released in time t per unit area.
             C = Drug initial concentration
             CS = drug solubility in matrix media 
             D = Diffusivity of drug molecules in matrix substance.
The  solid  line  represents  the  variation  of  drug  concentration  in  the
pharmaceutical system after time t. To distance h, the concentration gradient will
be constant, provided C>> Cs. The linearity order follows the Fick’s law.
)2( SS CCtDCQ −=  ------------- (9)
Relation  is  valid  during  all  time  except  when  the  total  depletion  of  drug  in
therapeutic system is achieved. Higuchi developed other models for release from
heterogeneous matrix, when the drug concentration in matrix is lower than its
solubility and the release occurs through pores in matrix, the obtained relation is:
ft = tCCC
T
DEQ SS )2( ε−=  ----------- (10)
Where, Є = matrix porosity.
Or,
Q = KH t ½ ------------ (11)
             Q = Cumulative amount of drug release at time t,
             KH = Higuchi constant.
The Higuchi equation suggests that the drug release by diffusion.
A graph  is  plotted between  the  square  root  of  time taken on X-axis  and  the
cumulative % of drug release on Y –axis and it gives a straight line.
Korsmeyer And Peppas Model: 
This equation is useful to study the diffusion / relaxation release of dosage form
as well zero order release kinetics. The equation can be described as
F = (Mt / M) = Km tn ---------- (12)
Where, F = fraction of drug released at time t,
             Mt = Amount of drug released at time t
             M =  Total amount of drug in dosage form
        Km = Kinetic constant
        n = Diffusion  or release exponent.
               t = Time in hours
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If n = 0.45 for Fickian diffusion, 
0 .45 <n< 0.89 for anomalous diffusion or non Fickian diffusion. 
n = 0.89  and above for case -2 relaxation or super case transport – 2. 
A graph is plotted between the log time taken on x-axis and the log cumulative %
of drug release on y-axis and it gives a straight line.
In order to study the drug release kinetics of the examined tablets, the dissolution
profiles  of  formulations  were  analyzed  according  to  zero-order,  first  order,
Higuchi's square root and Korsmeyer - Peppas equations.
12) Stability studies [52], [53], [54]:
The success of an effective formulation can be evaluated only through stability
studies. The purpose of stability testing is to obtain a stable product which assures
its safety and efficacy up to the end of shelf life at defined storage conditions and
pack profile.
The prepared floating tablets of Ciprofloxacin Hcl were placed in plastic tubes
containing  dessicant  and  stored  at  ambient  humidity  conditions,  at  room
temperature, oven temperature (40±2oC) and in refrigerator (2-8oC) for a period of
60 days.
The samples kept for stability were evaluated for the following physicochemical
parameters after 15, 30, 45 and 60 days for F2, F5, F6 and F7 batches.
Parameters evaluated:
i) Appearance
ii) Hardness
iii) Friability
iv) Floating test
v) Drug content
vi) In-vitro dissolution
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Hydrodynamically balanced tablets of Ciprofloxacin Hcl were prepared and evaluated
for their use as gastroretentive drug delivery systems to increase its bioavailability.
In the present study, seven formulations were prepared and the compositions of all the
batches are shown in Table 7.  The formulated tablets are shown in Figure 5.  The
tablets were characterized for various physicochemical parameters.
I. PREFORMULATION STUDIES:
a) Description:
Description of Ciprofloxacin Hcl was found to be faintly yellowish to light
yellow crystalline substance.
b) Solubility:
Ciprofloxacin Hcl was found to be soluble in water, 0.1N Hcl and practically
insoluble in acetone, acetonitrile and dichloromethane.
c) pH: pH of Ciprofloxacin Hcl was found to be 3.6
d) Compatibility Studies:
Compatibility studies were performed using FT-IR spectrophotometer and the
FTIR spectrum of the obtained drug and drug with polymers were studied. The
characteristic  absorption  peaks  of  Ciprofloxacin  obtained  at  3335.03cm-1,
3084.28cm-1 were  seen  in  the  FT-IR  spectrum  of  drug  with  polymers,
indicating  compatibility  of  drug  with  polymer  components.  The  FT-IR
spectrum of the drug and drug with polymers are shown in Figure 6 and 7
respectively. 
Figure 6: FT-IR spectrum of pure drug Ciprofloxacin Hcl
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Figure 7: FT-IR spectrum of Ciprofloxacin Hcl with HPMC (K100M, K4M and E50)
Table 10: FT-IR spectra data of pure drug Ciprofloxacin Hcl
Groups and mode of
vibrations
Frequency (in cm-1)
Drug Expected Range
NH stretching 3327.32 3500-3300
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C-N stretching
C-F stretching
C=C stretching
C=O carboxylic stretching
C-H stretching
O-H carboxylic stretching
1327.07
1379.15
1712.54
1728.33
3084.28
2976.26
1350-1000
1400-1000
1720-1708
1730-1700
3050-3010
3400-2400
II. EVALUATION OF FLOATING TABLETS OF CIPROFLOXACIN HCL:
A) Pre-Compression parameters:
The bulk density of granules value is used for determination of compressibility
index and hausner ratio.   
Compressibility  index  of  formulations  F1,  F3 and  F4 values  are  16.84%,
18.19% and 17.01% respectively indicate the pair flow property. Formulation
F2,  F5, F6 and F7  values are 14.23%, 12.60%, 13.20% and 14.23% respectively
indicate the good flow property.
Hausner ratio of formulations F1, F3 and F4 values are 1.20, 1.22% and 1.21%
respectively  indicate  the  pair  flow  property.  Formulation  F2,  F5, F6 and  F7
values  are  1.16,  1.14,  1.15  and  1.16  respectively  indicate  the  good  flow
property.
Angle of repose of formulations F1,  F3 and F4 values are 31.24, 32.65 and
31.37 respectively indicate the good flow property. Formulation F2,  F5, F6 and
F7 values are 28.42, 29.14, 27.34 and 28.30 respectively indicate the excellent
flow property.
Table 11: Pre-Compression Parameters
  
Parameters Formulation
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F1 F2 F3 F4 F5 F6 F7
Loose Bulk Density 
(gm/ml) 0.454 0.476 0.454 0.400 0.416 0.434 0.476
Tapped Bulk Density 
(gm/ml) 0.546 0.555 0.555 0.482 0.476 0.500 0.555
1.161.221.211.141.151.16C
ompressibility Index (%) 16.84 14.23 18.19 17.01 12.60 13.20 14.23
Angle of Repose (θ)1.20
Hausner Ratio 31.24 28.42 32.65 31.37 29.14 27.34 28.30
B) Post-Compression parameters:
1) Appearance:
Microscopic  examination  of  tablets  from each  batch  showed  white,  caplet
shape, biconvex, uncoated tablets plain on both sides.
2) Weight variation:
The percentage weight variations of all formulations are shown in Table 12.
The tablets  passed  weight  variation  test  as  % weight  variation  was  within
pharmacopoeial limits of ±5% of the average weight.
3) Thickness:
The thickness of all seven formulations values obtained from 5.58 mm to 5.64
mm.
The thickness of tablets are consumer acceptance  and to maintain tablet  to
tablet uniformity. It’s mostly related to tablet hardness. 
4) Hardness:
The hardness of formulations F3  value is 5.6 kg/cm2. Formulation F1  and F4
values are same 3.5 kg/cm2. Formulation F2, F5, F6 and F7 values obtained from
4.5 kg/cm2 to 5.0 kg/cm2. 
The  hardness  of  formulations  F3 is  highest  value  compare  to  other
formulations.  Formulation  F1  and  F4 is  lowest  value  compare  to  other
formulations.
5) Friability:
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% friability values obtained were less than 1% ensuring that the tablets were
mechanically stable.
6) Drug content:
The percentage drug content of the seven batches were found to be between
97.43%  to  99.90%,  which  is  within  acceptable  limits  indicating  dose
uniformity in each batch.
Table 12: Physicochemical Properties of Ciprofloxacin Floating Tablets
Parameters
Formulation
F1 F2 F3 F4 F5 F6 F7
Weight 
Variation (gm)
0.733±
0.019
0.729±
0.016
0.728±
0.022
0.731±
0.021
0.731±
0.014
0.733±
0.015
0.732±
0.013
Thickness 
(mm) 5.62 5.60 5.58 5.64 5.62 5.58 5.60
Hardness 
(kg/cm2) 3.5 4.5 6.5 3.5 4.5 5.0 5.0
Friability (%) 0.94 0.52 0.32 0.92 0.52 0.56 0.54
Drug Content 
(%) 99.90 98.67 97.43 99.63 98.12 98.82 99.09
7) Tablet density:
In order to have good floating behavior in the stomach, density of the system
should be less than that  of  the gastric  contents.  All  seven  batches  showed
density in the range of 0.92 – 0.94 g/cm3.
In the study it was clearly observed that the tablets of all batches showed good
floating characteristics after buoyancy lag time. This indicated that when the
tablet comes in contact with test medium, it expanded (because of swellable
polymer) and also there was formation of CO2 gas (because of effervescent
agent). 
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The  tablet  floated  as  density  dropped  below  1.0  due  to  the  expansion  of
polymer and upward force of CO2 gas generation.
 
Table 13: Tablet Density of Ciprofloxacin Floating Tablets
Parameters
Formulation
F1 F2 F3 F4 F5 F6 F7
Thickness 
(cm) 0.562 0.560 0.558 0.564 0.562 0.558 0.560
Length (cm) 1.716 1.720 1.716 1.718 1.722 1.720 1.716
Width (cm) 0.814 0.818 0.814 0.816 0.820 0.818 0.814
Tablet Density
(gm/cc) 0.93 0.93 0.94 0.93 0.92 0.93 0.94
8) Floating test:
Carbon dioxide is formed within the tablet containing effervescent agent when
it is brought in contact with acidic medium (0.1 N Hcl). 
On immersion in 0.1 N Hcl at 37oC, the tablets floated and remained buoyant
without  disintegration.  The  results  of  floating  lag  time  of  all  seven
formulations within 1 minute. Total floating time of F1 and F4 formulations are
more than 6 hours. Total floating time of F2,  F3,  F5,  F6  and F7  formulations are
more than 10 hours. Figure 8 shows buoyancy character of formulated tablets. 
Table 14: Floating Test of Ciprofloxacin Hcl Tablets
Parameters
Formulation
F1 F2 F3 F4 F5 F6 F7
Floating Lag Time
or Buoyancy Lag 
Time (sec)
12 30 50 10 35 15 20
Total Floating 
Time (hrs) >6 >10 >10 >6 >10 >10 >10
Figure 8: Buoyancy character of formulated tablets
Department of Pharmaceutics                     J.K.K.M.M.R.F College of Pharmacy
80
Chapter - 5                                                                                Results and Discussion
9) Swelling study:
Swelling  ratio  describes  the  amount  of  water  that  is  contained  within  the
hydrogel  at  equilibrium  and  is  a  function  of  the  network  structure,
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hydrophilicity  and  ionization of  the  functional  groups.  Swelling study was
performed on all the batches for 8 hours. The study showed that swelling of
tablet increased up to 4-5 hours for all formulations but after that it decreased.
The results of swelling index are given in Table 15, while the plot of swelling
index against  increases  with time because polymer gradually absorbs water
due to its hydrophilicity. The outermost layer of polymer hydrates, swells and
a  gel  barrier  is  formed  at  the  outer  surface.  As  the  gelatinous  layer
progressively  dissolves  and/or  is  dispersed,  the  hydration  swelling  release
process  is  repeated  towards  new  exposed  surfaces,  thus  maintaining  the
integrity of the dosage form.
Table 15: Swelling Index of Ciprofloxacin Floating Tablets
Time (hrs) Swelling Index (%)
F1 F2 F3 F4 F5 F6 F7
1 51.38 30.14 24.54 49.27 30.06 32.55 34.68
2 61.77 47.33 32.51 60.51 44.18 49.92 51.33
3 79.56 54.83 39.83 76.81 51.34 67.37 74.92
4 89.92 65.44 46.41 88.56 64.29 77.11 81.29
5 88.21 78.33 50.10 88.17 76.14 82.54 87.16
6 63.11 55.42 48.23 63.43 57.5576.44 79.13
7 32.15 39.22 41.11 32.98 42.18 59.15 54.24
8 17.18 27.93 39.87 17.26 29.46 30.29 29.35
Figure 9: Swelling Index of Ciprofloxacin Floating Tablets
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10) In-vitro Dissolution study:
Standard calibration curve of ciprofloxacin Hcl:
The λmax of Ciprofloxacin Hcl in 0.1 N Hcl was found to be 276 nm. The
absorbance values are tabulated in Table 16. Ciprofloxacin Hcl obeyed Beer’s
law in the concentration range of 5-30 µg/ml with regression coefficient  of
0.9993.  The  standard  calibration  curve  of  Ciprofloxacin  Hcl  is  shown  in
Figure 10.
Table 16: Absorbance of standard solutions of Ciprofloxacin Hcl
S.No. Concentration (µg/ml) Absorbance (276 nm)
1 5 0.186
2 10 0.349
3 15 0.562
4 20 0.747
5 25 0.942
6 30 1.124
Figure 10: Standard calibration curve of Ciprofloxacin Hcl
Department of Pharmaceutics                     J.K.K.M.M.R.F College of Pharmacy
83
Chapter - 5                                                                                Results and Discussion
Cumulative % drug release:
In-vitro drug release profile of tablets from each batch using USP dissolution
apparatus  Type  II  are  shown in Table 17.  The plot  of  % cumulative drug
released Vs. time (hr) was plotted for all formulations and depicted as shown
in Figure 11.
In  the  present  study  HPMC used  was  hydrophilic  in  nature,  drug  release
involves  (1)  hydration  and  swelling  of  polymer  and  dissolution  of  active
ingredients (2) transfer of the dissolved drug and soluble components into the
bulk.
The results of formulation F3 used HPMC (K100M, K4M and E50) for the
ratio of 1:1:1 was slow drug release of 79.98% within 10 hours. 
Formulation F1  ratio is 1:2:3 and F4 ratio is 2:1:3 were faster drug release of
99.82% and 99.34% respectively within 6 hours.
Formulations F2, F5, F6 and F7 used HPMC (K100M, K4M and E50) for the
ratio of 1:3:2, 2:3:1, 3:1:2 and 3:2:1 for drug release were 91.38%, 90.66%,
94.65% and 95.10% respectively.
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The  formulations  F2, F5, F6 and F7  are  found  to  be  satisfactory  with the
dissolution  profile  results.   Hence  these  formulations  are  kept  for  future
studies.
Table 17: In-vitro Dissolution study of Ciprofloxacin Floating Tablets
Time
(hrs)
Cumulative % Drug released
F1 F2 F3 F4 F5 F6 F7
1 32.69 22.93 17.72 30.39 22.12 27.25 29.40
2 45.08 32.20 21.45 42.16 30.55 38.71 40.85
3 59.26 46.25 29.83 51.73 43.14 50.22 54.62
4 72.37 51.07 35.76 69.98 49.72 55.34 61.73
5 81.61 59.14 40.41 80.93 56.43 63.66 74.43
6 99.82 67.31 49.92 99.34 65.18 75.76 80.17
7 72.43 57.33 70.92 79.38 82.59
8 80.27 65.04 78.71 80.70 85.10
9 88.79 74.37 86.12 89.26 91.48
10 91.38 79.98 90.66 94.65 95.10
Figure 11: In – vitro Dissolution study of formulated tablets
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11) Kinetics of drug release:
The  results  of  dissolution  data  were  fitted  to  various  drug  release  kinetic
equations.  Regression  coefficient  (R2)  value  was  highest  for  korsmeyer  –
peppas release equation in formulations F2, F5, F6 and F7.
The kinetics of drug release of R2 values obtained for formulations F2, F5, F6
and  F7 are  tabulated  in  Table  18.  The  drug  release  kinetics  obtained  for
formulations F2, F5, F6 and F7 are tabulated in Table 19, 20, 21 and 22.
Formulation F2  plots of Zero order, First order, Higuchi matrix, Korsmeyer -
Peppas and are depicted in Figure 12, 13, 14 and 15. Formulation F5  plots of
Zero order, First order, Higuchi matrix, Korsmeyer - Peppas and are depicted
in Figure 16, 17, 18 and 19. Formulation F6  plots of Zero order, First order,
Higuchi matrix, Korsmeyer - Peppas and are depicted in Figure 20, 21, 22 and
23. Formulation F7 plots of Zero order, First order, Higuchi matrix, Korsmeyer
- Peppas and are depicted in Figure 24, 25, 26 and 27.
The Zero order drug release graph is plotted between the time taken on x-axis
and the cumulative % of drug release on y-axis. 
First order drug release graph is plotted between the time taken on x-axis and
the log cumulative % of drug remaining on y-axis. 
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Higuchi’s square root graph is plotted between the square root of time taken
on x-axis and the cumulative % of drug release on y-axis.
Korsmeyer – Peppas drug release graph is plotted between the log time taken
on x-axis and the log cumulative % of drug release on y-axis.
The results of kinetic drug release of formulation F2, F5, F6 and F7  in the R2
values was highest for korsmeyer – peppas model.  The ‘n’ value obtained
from 0.521 to 0.633 indicates the non Fickian diffusion.
Table 18: Kinetics of drug release of R2 value for F2, F5, F6 and F7
Batch No.
Regression Coefficient (R2)
Zero Order First Order Higuchi
Korsmeyer - Peppas
R2 n
F2 0.9860 0.9511 0.9930 0.9944 0.612
F5 0.9920 0.9514 0.9928 0.9958 0.633
F6 0.9727 0.9342 0.9918 0.9940 0.542
F7 0.9366 0.9701 0.9837 0.9899 0.521
Table 19: Drug release kinetics of formulation F2
Time LogTime
Square
root of
Time
Cumulative
% Drug
Released
Log
Cumulativ
e % Drug
Released
Cumulative
% Drug
Remained
Log
Cumulative
% Drug
Remained
1 0 1 22.93 1.36 77.07 1.89
2 0.30 1.41 32.20 1.51 67.80 1.83
3 0.48 1.73 46.45 1.67 53.55 1.73
4 0.60 2 51.07 1.71 48.93 1.69
5 0.70 2.24 59.14 1.77 40.86 1.61
6 0.78 2.45 67.31 1.83 32.69 1.51
7 0.85 2.65 72.43 1.86 27.57 1.44
8 0.90 2.83 80.27 1.90 19.73 1.30
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9 0.95 3 88.79 1.95 11.21 1.05
10 1 3.16 91.38 1.96 8.62 0.94
Figure 12: Zero order drug release kinetics of formulation F2
Figure 13: First order drug release kinetics of formulation F2
Figure 14: Higuchi drug release kinetics of formulation F2
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Figure 15: Korsmeyer - Pepps drug release kinetics of formulation F2
Table 20: Drug release kinetics of formulation F5
Time LogTime
Square
root of
Time
Cumulative
% Drug
Released
Log
Cumulative
% Drug
Released
Cumulative
% Drug
Remained
Log
Cumulative
% Drug
Remained
1 0 1 22.12 1.34 77.88 1.89
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2 0.30 1.41 30.55 1.49 69.45 1.84
3 0.48 1.73 43.14 1.63 56.86 1.75
4 0.60 2 49.72 1.70 50.28 1.70
5 0.70 2.24 56.43 1.75 43.57 1.64
6 0.78 2.45 65.18 1.81 34.82 1.54
7 0.85 2.65 70.92 1.85 29.08 1.46
8 0.90 2.83 78.71 1.90 21.29 1.33
9 0.95 3 86.12 1.94 13.88 1.14
10 1 3.16 90.66 1.96 9.34 0.97
Figure 16: Zero order drug release kinetics of formulation F5
Figure 17: First order drug release kinetics of formulation F5
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Figure 18: Higuchi drug release kinetics of formulation F5
Figure 19: Korsmeyer - Pepps drug release kinetics of formulation F5
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Table 21: Drug release kinetics of formulation F6
Time LogTime
Square
root of
Time
Cumulative
% Drug
Released
Log
Cumulative
% Drug
Released
Cumulative
% Drug
Remained
Log
Cumulative
% Drug
Remained
1 0 1 27.25 1.44 72.75 1.86
2 0.30 1.41 38.71 1.59 61.29 1.79
3 0.48 1.73 50.22 1.70 49.78 1.70
4 0.60 2 55.34 1.74 44.66 1.65
5 0.70 2.24 63.66 1.80 36.34 1.56
6 0.78 2.45 75.76 1.88 24.24 1.38
7 0.85 2.65 79.38 1.90 20.62 1.31
8 0.90 2.83 80.70 1.91 19.30 1.29
9 0.95 3 89.26 1.95 10.74 1.03
10 1 3.16 94.65 1.98 5.35 0.73
Figure 20: Zero order drug release kinetics of formulation F6
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Figure 21: First order drug release kinetics of formulation F6
Figure 22: Higuchi drug release kinetics of formulation F6
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Figure 23: Korsmeyer - Pepps drug release kinetics of formulation F6
Table 22: Drug release kinetics of formulation F7
Time LogTime
Square
root of
Time
Cumulative
% Drug
Released
Log
Cumulative
% Drug
Released
Cumulative
% Drug
Remained
Log
Cumulative
% Drug
Remained
1 0 1 29.40 1.47 70.60 1.85
2 0.30 1.41 40.85 1.61 59.15 1.77
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3 0.48 1.73 54.62 1.74 45.38 1.66
4 0.60 2 61.73 1.79 38.27 1.58
5 0.70 2.24 74.43 1.87 25.57 1.41
6 0.78 2.45 80.17 1.90 19.83 1.30
7 0.85 2.65 82.59 1.92 17.41 1.24
8 0.90 2.83 85.10 1.93 14.90 1.17
9 0.95 3 91.48 1.96 8.52 0.93
10 1 3.16 95.10 1.98 4.90 0.69
Figure 24: Zero order drug release kinetics of formulation F7
Figure 25: First order drug release kinetics of formulation F7
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Figure 26: Higuchi drug release kinetics of formulation F7
Figure 27: Korsmeyer - Pepps drug release kinetics of formulation F7
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12) Stability studies:
Stability  studies  of  the  prepared  formulations  were  performed  at  ambient
humidity conditions,  at room temperature,  at  40oC and in refrigerator for a
period upto 60 days. The samples were withdrawn after a period of 15 days,
30 days, 45 days and 60 days and were analyzed for its appearance, hardness,
friability, floating test, drug content and in-vitro release.
The results obtained are tabulated in Table 23, 24, and 25. Results reveal no
significant changes in appearance, floating test and drug content. There was no
much variation either in hardness, friability and drug release in F2, F5, F6 and F7
formulations kept at the three storage conditions. Thus from the tables it is
evident  that  F2, F5, F6 and  F7 formulations  were  stable  at  all  three  storage
conditions up to a period of 30 days.  However F2, F5, F6 and F7 showed a
decrease in hardness after a period of 30 days,  with subsequent increase in
friability  and  in-vitro  drug  release,  for  samples  stored  at  prevailing  room
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temperature (34±2oC) and at 40oC, whereas there was no significant change in
F2, F5, F6 and  F7 formulations  stored  in  refrigerator.  Thus  from the  above
results it can be concluded that Ciprofloxacin floating tablets are stable when
stored at 2 to 8oC.
Table 23: Formulations F2, F5, F6 and F7 stored at Room Temperature
Formu
lation
Tested
after
time
(days)
Hardness
(kg/cm2)
Friability
(%)
Floating Test Drug
Content
(%)
Cum. %
Drug
Released
(in 10th
hours)
BLT
(sec)
TFT
(hrs)
F2
15
30
45
60
4.5
4.5
4.4
4.4
0.52
0.53
0.53
0.56
30
30
31
32
>10
>10
>10
>10
98.46
98.21
97.82
97.53
91.21
90.76
90.54
90.07
F5
15
30
45
60
4.5
4.5
4.4
4.3
0.52
0.52
0.53
0.54
35
35
37
38
>10
>10
>10
>10
98.06
97.86
97.59
97.16
90.47
90.18
89.74
89.35
F6
15
30
5.0
4.9
4.9
0.56
0.56
0.57
15
15
16
>10
>10
>10
98.63
98.31
98.11
94.28
94.02
93.88
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45
60 4.8 0.58 17 >10 97.88 93.57
F7
15
30
45
60
4.5
4.5
4.4
4.3
0.54
0.54
0.55
0.55
20
20
21
22
>10
>10
>10
>10
98.94
98.67
98.39
98.04
95.02
94.85
94.43
94.17
Table 24: Formulations F2, F5, F6 and F7 stored at 40oC
Formu
lation
Tested
after
time
(days)
Hardness
(kg/cm2)
Friability
(%)
Floating Test Drug
Content
(%)
Cum. %
Drug
Released
(in 10th
hours)
BLT
(sec)
TFT
(hrs)
F2
15
30
45
60
4.5
4.4
4.3
4.2
0.52
0.53
0.54
0.57
30
31
32
34
>10
>10
>10
>10
98.38
98.17
97.65
97.48
91.17
90.68
90.42
90.01
F5
15
30
45
60
4.5
4.4
4.4
4.3
0.52
0.54
0.55
0.56
35
36
37
38
>10
>10
>10
>10
97.96
97.69
97.37
96.85
90.28
90.03
89.69
89.27
F6
15
30
45
5.0
4.9
4.8
0.56
0.58
0.58
15
16
16
>10
>10
>10
98.59
98.27
98.07
94.15
93.94
93.56
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60 4.7 0.59 17 >10 97.65 93.31
F7
15
30
45
60
4.5
4.4
4.3
4.3
0.54
0.55
0.56
0.58
20
21
21
22
>10
>10
>10
>10
98.82
98.59
98.17
97.84
94.89
94.64
94.37
94.12
Table 25: Formulations F2, F5, F6 and F7 stored in Refrigerator (2-8oC)
Formu
lation
Tested
after
time
(days)
Hardness
(kg/cm2)
Friability
(%)
Floating Test Drug
Content
(%)
Cum. %
Drug
Released
(in 10th
hours)
BLT
(sec)
TFT
(hrs)
F2
15
30
45
60
4.5
4.5
4.5
4.4
0.52
0.52
0.53
0.53
30
30
31
31
>10
>10
>10
>10
98.62
98.47
98.16
97.94
91.28
90.81
90.69
90.41
F5
15
30
45
60
4.5
4.5
4.5
4.4
0.52
0.52
0.53
0.53
35
35
36
37
>10
>10
>10
>10
98.07
97.91
97.73
97.62
90.52
90.37
89.99
89.63
F6
15
30
45
60
5.0
4.9
4.9
4.9
0.56
0.56
0.56
0.57
15
15
16
16
>10
>10
>10
>10
98.76
98.49
98.25
98.18
94.47
94.18
94.02
93.86
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F7
15
30
45
60
4.5
4.5
4.4
4.4
0.54
0.54
0.54
0.55
20
20
20
21
>10
>10
>10
>10
99.02
98.93
98.74
98.51
95.06
94.97
94.75
94.53
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SUMMARY
• Compounding  drugs  having  narrow  absorption  window  in  a  unique
pharmaceutical  dosage  form  with  gastro  retentive  properties  would  enable  an
extended absorption phase of these drugs. 
• After oral administration, such a dosage form is retained in the stomach and
releases  the  drug  in  a  controlled  and  prolonged  manner,  so  that  the  drug  is
supplied continuously to its absorption sites in the upper gastrointestinal tract.
• In  the  present  study  an  attempt  was  made  to  formulate  Ciprofloxacin  as
floating drug delivery system in order to enhance its bioavailability and to localize
drug at the absorption site. 
• Floating  tablets  of  Ciprofloxacin  Hcl  were  formulated  using  sodium
bicarbonate as gas  generating agent  and HPMC as water swellable polymer by
direct compression technique.
• FT-IR  spectral  studies  revealed  that  the  drug  and  polymer  used  were
compatible.
• These  formulations  were  subjected  to  various  evaluation  parameters  like
weight  variation,  thickness,  hardness,  friability,  drug  content,  tablet  density,
floating test, swelling index, in-vitro release studies and stability studies. 
• The results of all these parameters are tabulated and depicted graphically in
the result and discussion section.
• Evaluation  parameters  viz.  tablet  weight  variation,  thickness,  friability  and
drug content were within acceptable limits for all seven formulations. 
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• All seven formulations showed satisfactory results for tablet density, floating
test and swelling studies.
• Results of in-vitro release using USP dissolution apparatus Type II  method
indicated that the drug release of formulations F2, F5, F6 and F7 are satisfactory.
• The results of kinetic drug release of formulation F2, F5, F6 and F7  in the R2
values was highest for korsmeyer – peppas model.  
• Stability studies showed F2, F5, F6 and F7 to be stable at room temperature, 40oC
and 2-8oC for a period of 60 days.  F2, F5, F6 and F7 formulations were stable at all
three  storage  conditions up to  a  period of  30 days.  However F2, F5, F6 and F7
showed a decrease in hardness after a period of 30 days, with subsequent increase
in  friability  and  in-vitro  drug  release,  for  samples  stored  at  prevailing  room
temperature (34±2oC) and at 40oC. No significant change was observed in F2, F5, F6
and F7 formulation stored in refrigerator.  This suggested that  the most suitable
storage temperature for Ciprofloxacin floating tablets is 2-8oC. 
CONCLUSION
• Hydrodynamically balanced tablets of Ciprofloxacin Hcl
can  be  formulated  with an  approach  to  increase  gastric  residence  and  thereby
improve drug bioavailability.
• An attempt to  develop floating tablets of  Ciprofloxacin
Hcl, using sodium bicarbonate as gas generating agents and HPMC as hydrophilic
polymer by direct compression technique was achieved.
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• The  formulated  tablets  showed  compliance  for  various
physiochemical  parameters  viz.  tablet  dimensions,  total  floating  time,  tablet
density and drug content.
• The  dissolution  studies  formulations  of  F2, F5, F6 were
good release                     and F7 formulation was excellent.
• Data obtained from kinetic treatment revealed F2, F5, F6
and F7 formulations follow Korsmeyer – peppas model. The ‘n’ value obtained
from 0.521 to 0.633 indicates the non Fickian diffusion.
• The  results  of  stability  studies  indicated  that  the  most
suitable storage  temperature  for  Ciprofloxacin floating tablets was 2-8oC for  a
period of 60 days.
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